

## 研究成果の刊行に関する一覧表

## 書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
Tohru Ohama, Ryota Kawase, Yasushi Sakata, Shinizuya Yamashita	Chapter 21 Methods for studying the function of progranulin in atherosclerosis using both knockout mice models and in vitro studies	Andrew Bateman, Hugh P.J. Bennett, Siu Tim Cheung	Methods in Molecular Biology 1806 Springer Protocols: Progranulin Methods and Protocols	Humana Press	USA	2018	315-328
Shizuya Yamashita, Yuji Matsuzawa	Low HDL and high HDL syndromes	Luciano Martini	Encyclopedia of Endocrine Diseases, Second Edition	Elsevier	USA	2018	327-339
川尻剛照、山岸正和	脂質異常症の治療薬	小室一成、中村正人	循環器内科専門医バイブルシリーズ「虚血性心疾患」虚血性心疾患の二次予防	中山書店	東京	2018	300-305
川尻剛照、山岸正和	安定狭心症	伊藤浩、山下武志	循環器疾患最新の治療2018-2019	南江堂	東京	2018	83-86
三井田孝	TGの測定法と標準化	倉林正彦	高TG血症	最新医学社	大阪	2018	94-100
三井田孝	鑑別診断手順	日本動脈硬化学会	脂質異常症診療ガイド	日本動脈硬化学会	東京	2018	26-28
三井田孝	LDL-C測定法に計算式と直接法がありますが使い分ければよいですか？違いと使い方を教えてください	日本動脈硬化学会	脂質異常症診療ガイド	日本動脈硬化学会	東京	2018	142
三井田孝	LDL-C直接法は不正確だと聞きましたが本当ですか？	日本動脈硬化学会	脂質異常症診療ガイド	日本動脈硬化学会	東京	2018	142
三井田孝	中性脂肪	日本衛生検査所協会	50人の専門医が教える検査と検査値の話	日本衛生検査所協会	東京	2018	86-87

三井田孝	食事時間と検査値	日本衛生検査所協会	50人の専門医が教える検査と検査値の話	日本衛生検査所協会	東京	2018	128-129
小倉正恒、和田郁人、斯波真理子	原発性高TG血症治療の現状と新薬開発状況	倉林正彦	高TG血症	最新医学社	大阪	2018	184-191
佐々木誠、池脇克則	高TG血症とHDL代謝	倉林正彦	高TG血症	最新医学社	東京	2018	60-6
高曾根健、関島良樹	脳腱黄色腫症	水澤英洋, 五十嵐隆, 北川泰久, 高橋和久, 弓倉整	指定難病ペディア2019	日本医師会	東京	2019	275-276
土橋一重	家族性高コレステロール血症	五十嵐隆	小児科診療ガイドライン第4版	総合医学社	東京	2019	528-532
三井田孝	低HDL-C血症	磯部光章、竹本稔、前嶋康浩、弓倉整、横手幸太郎	動脈硬化診療のすべて	日本医師会	日本医師会	2019	S94-S97
小倉正恒	LDL-Cを下げる	伊藤浩	そうだったんだ！脂質異常省第2版	文光堂	東京	2020	160-173
塚本和久	シトステロール血症	水澤英洋、五十嵐隆、北川泰久、高橋和久、弓倉整	指定難病ペディア2019、日本医師会雑誌生涯教育シリーズ96	診断と治療社	東京	2019	280
塚本和久	高LDLコレステロール血症	片山茂裕、猿田享男	私の治療	日本医事新報	東京	2019	42
塚本和久	高トリグリセライド血症	片山茂裕、猿田享男	私の治療	日本医事新報	東京	2019	43

内野卓也、 塚本和久	脂質異常症の病態 と診断	伊藤浩	そうだったん だ！脂質異常 症	文光堂	東京	2020	77-82
塚本和久	シトステロール血 症	永井良三	今日の診断指 針 第8版	医学書院	東京	2020	1199-1201
小山信吾	脳腱黄色腫症		Current Decision Support 『今日 の疾患辞典』 デジタル版	株式会社 プレジ ジョン		2019	
斯波真理 子	小児脂質異常症	水口雅, 市 橋光, 崎山 弘, 伊藤秀 一	今日の小児治 療指針 第17 版	医学書院		2020	253
小倉正恒	VI: 脂質異常症の 治療 3. LDL-Cを下げる	伊藤浩	そうだったん だ！脂質異常 症(第2版)治 療の新潮流を 探る	文光堂	東京	2020	160-173
小倉正恒		小倉正恒	見直し！脂質 異常症 あな たも名医！ 評価・処方 の“いま”を 押さえる	日本医事 新報社	東京	2020	全197ペ ージ(企 画編集)
小倉正恒	5章. 各疾患・ライ フステージの心 血管イベントリ スク・治療の 違いを知ろう！	小倉正恒	見直し！脂質 異常症 あな たも名医！ 評価・処方 の“いま”を 押さえる	日本医事 新報社	東京	2020	145-148
山下静也	II 脂質異常症の 病態と診断 3. LD Lの目標値はな ぜ病態で異なる？	伊藤浩	そうだったん だ！脂質異常 症【第2版】治 療の新潮流を 探る	文光堂	東京	2020	61-67

山下静也	2. 代謝・内分泌検査/B.脂質代謝総コレステロール	大西宏明、Medical Practice編集委員会：矢崎義雄、小池和彦、小室一成、須永眞司、山内敏正	臨床検査ガイド2020年改訂版 これだけ必要な検査のすすめかた・データのよみかた	文光堂	東京	2020	287-294
石垣 泰	脂質異常症—高LDLコレステロール血症		今日の治療指針	医学書院		2019	745-750
野原 淳	2章 薬を知ろう！「4. 家族性高コレステロール血症ホモ接合体の治療, MTP阻害薬とアフェレシスについて教えて下さい」	小倉 正恒	見直し！脂質異常症 あなたも名医！評価・処方“いま”を押さえる	日本医事新報社	東京	2020	52-62
野原 淳	I 症候編 1. 全身的にみられる症候「脂質異常症」	永井 良三 (総編集), 浅利靖 (ほか責任編集)	今日の診断指針 第8版	医学書院		2020	123-126
多田隼人	LDL-C値が高い患者に遭遇したら？	小倉 正恒	見直し！脂質異常症	日本医事新報社	東京	2020	63-68
塚本和久	シトステロール血症	永井良三、総編集	今日の診断指針 第8版	医学書院		2020	1199-1201
岡崎啓明	TG値が高い患者に遭遇したら？	小倉 正恒	見直し！脂質異常症	日本医事新報社	東京	2020	
内野卓也、塚本和久	脂質異常症の病態と診断、血液検査による評価	伊藤浩	そうだったんだ！脂質異常症	文光堂	東京	2020	77-82
原眞純、塚本和久	脂質異常症の治療計画	高血圧・循環器病予防療養指導士認定委員会	高血圧と循環器病の予防と管理 第二版	株式会社社会保険研究所		2020	259-265
塚本和久	脂質異常症—高LDLコレステロール血症	福井次矢、高木誠、小室一成	今日の治療指針 2021年版—私はこう治療している	医学書院		2021	774-777

山下静也	第VI章 内分泌・代謝系疾患 動脈硬化性疾患予防ガイドライン2017年版(2017)/NEW 動脈硬化性疾患予防のための脂質異常症治療ガイド2018年版(2018)	門脇 孝、小室一成、宮地良樹	日常診療に活かす診療ガイドラインUP-TO-DATE 2020-2021(2) 脂質異常症	メディカルレビュー社		2020	405-412
山下静也	第22章 脂質異常症用薬	監修：矢崎義雄、編集：松澤佑次、永井良三、伊藤貞嘉、松原和夫	ポケット判治療薬UP-TO-DATE 2020	メディカルレビュー社		2020	320-340
山下静也	第22章 脂質異常症用薬	監修：矢崎義雄、編集：松澤佑次、永井良三、伊藤貞嘉、松原和夫	ポケット判治療薬UP-TO-DATE 2021	メディカルレビュー社		2021	
川尻剛照			その患者、FHかもしれないよ？	メディカル出版	大阪	2021	136
小関正博、坂田泰史	脂質代謝の正常と異常	伊藤浩、坂田泰史	臨床循環器学	文光堂	日本	2021	222-229

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hori M, Miyauchi E, Son C, Harada-Shiba M	Detection of the benign c.2579C>T (p.A860V) variant of the LDLR gene in a pedigree-based genetic analysis of familial hypercholesterolemia.	J Clin Lipidol		in press	2019
Harada-Shiba M	How much further do we need to decrease LDL cholesterol levels in heterozygous familial hypercholesterolemia?	Atherosclerosis		in press	2019
Shirahama R, Ono T, Nagamatsu S, Sueta D, Takashio S, Chubutose T, Fujisue K, Sakamoto K, Yamamoto E, Izumiya Y, Kaikita K, Hokimoto S, Hori M, Harada-Shiba M, Kajiwara I, Ogawa H, Tsujita K	Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation	Intern Med	57	3551-3557	2018
Nose D, Hori M, Miyamoto Y, Imaizumi S, Harada-Shiba M, Saku K, Miura S	Discontinuation of LDL apheresis with evolocumab in an FH patient with a duplication of exon 2-6 in the LDLR gene	Journal of Cardiology Case		in press	2019
Nohara A, Otsubo Y, Yanagi K, Yoshida M, Ikewaki K, Harada-Shiba M, Jurecka A	Safety and Efficacy of Lovastatin in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study	J Atheroscler Thromb		in press	2019
Vallejo-Vaz A, Harada-Shiba M, Yamashita S, Catapano AL, Ray KK et al; On behalf of the EAS Familial Hypercholesterolemia Studies Collaboration (FHSC) Investigators	Overview of the current status of familial hypercholesterolemia care in over 60 countries - The EAS Familial Hypercholesterolemia Studies Collaboration (FHSC)	Atherosclerosis	277	234-255	2018

Harada-Shiba M, Ako J, Arai H, Hirayama A, Murakami Y, Nohara A, Ozaki A, Uno K, Nakamura M	Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: results of the EXPLORE-J study	Atherosclerosis	277	362-368	2018
Kakuta T, Fujita T, Fukushima S, Kawamoto N, Matsumoto Y, Yamashita K, Shimahara Y, Ishibashi-Ueda H, Harada-Shiba M, Kobayashi J	Two Cases of Surgical Management of Supravalvular Aortic Stenosis in Familial Hypercholesterolemia	Ann Thorac Surg	105(4)	e171-e174	2018
Harada-Shiba M, Arai H, Ishigaki Y, Ishibashi S, Okamura T, Ogura M, Dobashi K, Nohara A, Bujo H, Miyaudhi K, Yamashita S, Yokote K, Working Group by Japan Atherosclerosis Society for Making Guidance of Familial Hypercholesterolemia	Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia. 2017	J Atheroscler Thromb	25	751-770	2018
Kameyama N, Maruyama C, Kitagawa F, Nishii K, Uenomachi K, Katayama Y, Koga H, Chikamoto N, Kuwata Y, Torigoe J, Arimoto M, Tokumaru T, Ikewaki K, Nohara A, Otsubo Y, Yanagi K, Yoshida M, Harada-Shiba M	Dietary intake during 56 weeks of a low-fat diet for orlistat treatment in Japanese patients with homozygous familial hypercholesterolemia	J Atheroscler Thromb	26	72-83	2019

Harada-Shiba M, Ohta T, Ohtake A, Ogura M, Dobashi K, Nohara A, Yamashita S, Yokote K Joint Working Group by Japan Pediatric Society and Japan Atherosclerosis Society for Making Guidance of Pediatric Familial Hypercholesterolemia	Guidance for Pediatric Familial Hypercholesterolemia 2017	J Atherosclerosis Thromb	25	539-553	2018
Harada-Shiba M, Kastelein J-P, Hovingh GK, Kausik R, Ohtake A, Arisaka O, Ohta T, Okada T, Suganami H, Wiegman A	Efficacy and safety of pitavastatin in children and adolescents with familial hypercholesterolemia in Japan and Europe	J Atherosclerosis Thromb	25	422-429	2018
Cesare R, Sirtori CR, Shizuya Yamashita M, Maria Francesca Greco, Alberto Corsini, Gerald Watts, Massimiliano Ruscica	Recent advances in synthetic pharmacotherapies for dyslipidemias.	European Journal of Preventive Cardiology		in press	
Yamashita S, Masuda D, Matsuzawa Y	Clinical applications of a novel selective PPAR $\alpha$ modulator, pemafibrate, in dyslipidemia and metabolic diseases.	J Atherosclerosis Thromb		in press	
Sairyo M, Kobayashi T, Masuda D, Kanno K, Zhu Y, Okada T, Koseki M, Ohshima T, Nishida M, Sakata Y, Yamashita S	A novel selective PPAR $\alpha$ modulator (SPPARM $\alpha$ ), K-877 (pemafibrate), attenuates postprandial hypertriglyceridemia in mice	J Atherosclerosis Thromb	25	142-152	2018
Okada T, Ohama T, Okazaki M, Kanno K, Masuda H, Sairyo M, Zhu Y, Sagaya A, Kobayashi T, Masuda D, Koseki M, Nishida M, Sakata Y, Yamashita S	Particle number analysis of lipoprotein subclasses by gel permeation HPLC in patients with cholesterol ester transfer protein deficiency.	PLoS One	13	e0190875	2018



Teramoto T, Kaji T, Ozaki A, Crawford B, Arai H, Yamashita S	Treatment patterns and lipid profile in patients with familial hypercholesterolemia in Japan.	J Atheroscler Thromb	25	580-592	2018
Yamashita S, Masuda D, Arai H, Matsuzawa Y	Cultural barriers in the treatment of dyslipidemia: a survey of Japanese physician attitudes.	J Atheroscler Thromb	26	154-169	2019
Sturm CA, KnowlesWJ, Gidding SS, Ahmad SZ, Ahmed DC, Ballantyne MC, Barum JS, Bourbon M, Cuchel M, Hovingh K, Kastlein PJ, Lane RS, Nordestgaard GB, Santos RD, Harada-Shiba M, Sijbrands E, Yamashita S, Wilemon KA, Pedersen DT	Convened by the Familial Hypercholesterolemia Foundation: Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel.	J Am Coll Cardiol	72	662-680	2018
EAS Familial Hypercholesterolemia Studies Collaboration; Vallejo-Vaz AJ, Harada-Shiba M, Yamashita S, et al; On behalf of the EAS Familial Hypercholesterolemia Studies Collaboration (FHSC) investigators	Overview of the current status of and initiatives related to familial hypercholesterolemia in over 60 countries participating in the EAS familial hypercholesterolemia studies collaboration (FHSC).	Atherosclerosis	277	234-255	2018

<p>Committee for Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.</p> <p>Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daida H, Tsukamoto K, Deguchi J, Dohi S, Dobashi K, Hamaguchi H, Harara M, Hiro T, Biro S, Fujioaka Y, Maruyama C, Miyamoto Y, Murakami Y, Yokode M, Yoshida H, Rakugi H, Wakatsuki</p>	<p>J Atheroscler Thromb</p>	<p>25</p>	<p>846-984</p>	<p>2018</p>
<p>Pang J, Chan D-C, Hu M, Muir LA, Kwok S, Charnng M-J, Florowski CM, George P, Lin J, Marais AD, Nawawi HM, Gonzalez-Santos LE, Su T-C, Truong TH, Santos RD, Soran H, Tomlinson B, Yamashita S, Ademi Z, Watts GF</p>	<p>Comparative aspects of the care of familial hypercholesterolaemia in the "Ten Countries Study.</p>	<p>J Clin Lipidol.</p>	<p>in press</p>	
<p>Nishino T, Horiuchi T, Baba O, Sawawa N, Hanada R, Kuwabara Y, Nakaoka T, Nishigaki M, Nishi H, Nakashima Y, Nakazeki F, Ide Y, Koyama S, Kimura M, Nagata M, Yoshida K, Takagi Y, Nakamura T, Hasegawa K, Miyamoto S, Kimura T, and *Ono K</p>	<p>SREBF1/MicroRNA-33b axis exhibits potent effect on unstable atherosclerotic plaque formation in vivo.</p>	<p>Arterioscler Thromb Vasc Biol.</p>	<p>38</p>	<p>2460-2473 2018</p>

Baba O, Horie T, Nakao T, Hakuono D, Nakashima Y, Nishi H, Kuwabara Y, Nishiga M, Nishino T, Ide Y, Nakazeki F, Koyama S, Kimura M, Hanada R, Kawahara M, Kimura T, and *Ono K	MicroRNA-33 regulates the population of peripheral inflammatory Ly6Chigh monocytes through dual pathways	Mol Cell Bio	38	e00604-17	2018
Ono K, Kuwabara Y, Horie T, Kimura T.	Long Non-Coding RNAs as Key Regulators of Cardiovascular Diseases	Circulation J.	82	1231-1236	2018
Tada H, Inaba S, Pozharitckaia D, Kawashiri MA.	Prominent Tendon Xanthomas and Abdominal Aortic Aneurysm Associated with Cerebrotendinous Xanthomatosis Identified Using Whole Exome Sequencing.	Intern Med.	57	1119-1122	2018
Nakahashi T, Tada H, Sakata K, Yakuta Y, Tanaka Y, Nomura A, Gamou T, Terai H, Horita Y, Ikeda M, Namura M, Takamura M, Hayashi K, Yamagishi M, Kawashiri MA.	Paradoxical impact of decreased low-density lipoprotein cholesterol level at baseline on the long-term prognosis in patients with acute coronary syndrome.	Heart Vessel	33	695-705	2018
Tada H, Kawashiri MA, Nohara A, Inazu A, Mabuchi H, Yamagishi M.	Assessment of arterial stiffness in patients with familial hypercholesterolemia.	J Clin Lipidol.	12	397-402	2018
Okada H, Tada H, Hayashi K, Kawashima H, Tanakata T, Sakata K, Nohara A, Mabuchi H, Yamagishi M, Kawashiri MA.	Aortic Root Calcification Score as an Independent Factor for Predicting Major Adverse Cardiac Events in Familial Hypercholesterolemia.	J Atheroscler Thromb.	25	634-642	2018
Nomura A, Tada H, Nohara A, Kawashiri MA, Yamagishi M.	Oral Fat Tolerance Test for Sitosterolemia and Familial Hypercholesterolemia: A Study Protocol.	J Atheroscler Thromb.	25	741-746	2018

Nakahashi T, Tada H, Sakata K, Nomura A, Ohtsuka M, Hira M, Mori M, Takamura M, Hayashi K, Yamagishi M, Kawashiri MA.	Additive Prognostic Value of Carotid Plaque Score to Enhance the Age, Creatinine, and Ejection Fraction Score in Patients with Acute Coronary Syndrome.	J Atheroscler Thromb.	25	709-719	2018
Tada H, Kawashiri MA, Nohara A, Sakata K, Inazu A, Mabuchi H, Yamagishi M, Hayashi K.	Remnant-like particles and oxidized low-density lipoprotein in familial hypercholesterolemia.	Clin Chim Acta.	482	120-123	2018
Kawashiri MA, Tada H, Nomura A, Yamagishi M.	Mendelian randomization: Its impact on cardiovascular disease.	J Cardiol.	72	307-313	2018
Tada H, Nomura A, Nohara A, Inazu A, Mabuchi H, Yamagishi M, Kawashiri MA.	Post-prandial Remnant Lipoprotein Metabolism in Sitosterolemia.	J Atheroscler Thromb.	25	1188-1195	2018
Tada H, Nomura A, Yamagishi M, Kawashiri MA.	First case of sitosterolemia caused by double heterozygous mutations in ABCG5 and ABCG8 genes.	J Clin Lipidol.	12	1164-1168	2018
Tada H, Nohara A, Inazu A, Sakuma N, Mabuchi H, Kawashiri MA.	Sitosterolemia, Hypercholesterolemia, and Coronary Artery Disease.	J Atheroscler Thromb.	25	783-789	2018
Tada H, Kawashiri MA, Nomura A, Yoshimura K, Itoh H, Komuro I, Yamagishi M.	Serum triglycerides predict first cardiovascular events in diabetic patients with hypercholesterolemia and retinopathy.	Eur J Prev Cardiol.	25	1852-1860	2018
Tada H, Kawashiri MA, Nomura A, Teramoto R, Hosomichi K, Nohara A, Inazu A, Mabuchi H, Tajima A, Yamagishi M.	Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease.	J Clin Lipidol.	12	1436-1444	2018
Tada H, Nohara A, Kawashiri MA.	Serum Triglycerides and Atherosclerotic Cardiovascular Disease: Insights from Clinical and Genetic Studies.	Nutrients.	10		2018

Nomura A, Tada H, Okada H, Nohara A, Ishikawa H, Yoshimura K, Kawashiri MA.	Impact of genetic testing on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia (GentLe-FH): a randomised waiting list controlled open-label study protocol.	BMJ Open.	8	E023636	2018
Tada H, Kawashiri MA.	Genetic Variations, Triglycerides, and Atherosclerotic Disease.	J Atheroscler Thromb.	26	128-131	2019
Tada H, Nomura A, Okada H, Nakahashi T, Nogazue T, Hayashi K, Nohara A, Yagi K, Inazu A, Michishita I, Mabuchi H, Yamagishi M, Kawashiri MA.	Clinical whole exome sequencing in severe hypertriglyceridemia.	Clin Chim Acta.	488	31-39	2019
Tada H, Nohara A, Inazu A, Mabuchi H, Kawashiri MA.	Remnant lipoproteins and atherosclerotic cardiovascular disease.	Clin Chim Acta.	490	1-5	2019
Okada H, Nakanishi C, Yoshida S, Shimojima M, Yokawa J, Mori M, Tada H, Yoshimuta T, Hayashi K, Yamano T, Hanayama R, Yamagishi M, Kawashiri MA.	Function and Immunogenicity of Gene-corrected iPSC-derived Hepatocyte-Like Cells in Restoring Low Density Lipoprotein Uptake in Homozygous Familial Hypercholesterolemia.	Sci Rep.	9	4965	2019
Nagahara K, Hachiya R, Tada H, Okada H, Yamagishi M, Dobashi K, Mizuno K, Hasegawa Y.	A Japanese case of familial hypercholesterolemia with a novel mutation in the LDLR gene.	Clin Ped Endocrinol	29	19-22	2018

Takanashi M, Kimura T, Li C, Tanaka M, Matsuhashi A, Yoshida H, Noda A, Xu P, Takase S, Okazaki S, Iizuka Y, Kumagai H, Ikeda Y, Gotoda T, Takahashi M, Yagyu H, Ishibashi S, Yamauchi T, Kadowaki T, Liang G, Okazaki H	Critical Role of SREBP-1c in Large-VLDL Pathway in Environment-Induced Hypertriglyceridemia of Apo AV Deficiency.	Arteriosclerosis Thromb Vasc Biol	39(3)	373-386	2019
Eguchi J, Miyashita K, Fukumachi I, Nakajima K, Murakami M, Kawahara Y, Yamashita T, Ohta Y, Abe K, Nakatsuka A, Mino M, Takase S, Okazaki H, Hegele RA, Ploug M, Hu X, Wada J, Young SG, Beigneux AP	GPIIb/IIIa autoantibody syndrome during interferon $\beta$ treatment.	J Clin Lipidol.	13(1)	62-69	2019
Nohara A, Ohmura H, Okazaki H, Ogura M, Kitagawa K, Koseki M, Sato K, Tsukamoto K, Yamashita S; Japan Atherosclerosis Society Working Group for Statement for Appropriate Use of PCSK9 Inhibitors	Statement for Appropriate Clinical Use of PCSK9 Inhibitors.	J Atherosclerosis Thromb	25(8)	747-750	2018
Nagasaka H, Hirano K, Yorifuji T, Komatsu H, Takatani T, Morioka I, Hirayama S, Miida T.	Treatment with medium chain fatty acids milk of CD36-deficient preschool children.	Nutrition	50	45-48	2018

Isshiki M, Hirayama S, Ueno T, Ito M, Furuta A, Yano K, Yamatani K, Sugihara M, Idei M, Miida T	Apolipoproteins C-II and C-III as nutritional markers unaffected by inflammation.	Clin Chim Acta	481	225-230	2018
Hirayama S, Nagasaka H, Honda A, Komatsu H, Kodama T, Inui A, Morioka I, Kaji S, Ueno T, Ihara K, Yagi M, Kizaki Z, Bessho K, Kondou H, Yorifuji T, Tsukahara H, Iizima K, Miida T	Cholesterol metabolism is enhanced in the liver and brain of children with citrin deficiency.	J Clin Endocrinol Metab	103(7)	2488-2497	2018
Yamashita Y, Nakada S, Yoshihara T, Nara T, Furuya N, Miida T, Hattori N, Arikawa-Hirasawa E.	Perlecan, a heparan sulfate proteoglycan, regulates systemic metabolism with dynamic changes in adipose tissue and skeletal muscle.	Sci Rep	8(1)	7766	2018
Ishibashi R, Takemoto M, Tsurutani Y, Kuroda M, Ogawa M, Wakabayashi H, Uesugi N, Nagata M, Imai N, Hattori A, Sakamoto K, Kitamoto T, Maezawa Y, Narita I, Hiroi S, Furuta A, Miida T, Yokote K.	Immune-mediated acquired lecithin-cholesterol acyltransferase deficiency: A case report and literature review.	J Clin Lipidol	12(4)	888-897	2018
Yano K, Hirayama S, Misawa N, Furuta A, Ueno T, Motoi Y, Seino U, Ebinuma H, Ikeuchi T, Schneider WJ, Bujo H, Miida T	Soluble LR11 competes with amyloid $\beta$ in binding to cerebrospinal-fluid-high-density lipoprotein.	Clin Chim Acta	489	29-34	2019

Sekijima Y, Koyama S, Yoshinaga Y, Koinuma M, Inaba Y.	Nationwide survey on cerebrotendinous xanthomatosis in Japan	J Hum Genet	63	271-280	2018
Sharma R, Matsuzaka T, Kaushik MK, Sugasawa T, Ohno H, Wang Y, Motomura K, Shimura T, Okajima Y, Mizunoe Y, Ma Y, Saber ZM, Iwasaki H, Yatoh S, Suzuki H, Aita Y, Han SI, Takeuchi Y, Yahagi N, Miyamoto T, Sekiya M, Nakagawa Y, Shimano H.	Octacosanol and policosanols prevent high-fat	Sci Rep.	26;9(1)	5169.	2019 Mar
Shichino S, Ueha S, Hashimoto S, Otsuji M, Abe J, Tsukui T, Deshimaru S, Narykajima T, Kosugi-Kanaya M, Shand FH, Inagaki Y, Shimano H, Matsushima K.	Transcriptome network analysis identifies protective role of the LXR/SREBP-1c axis in murine pulmonary fibrosis.	JCI Insight.	10;4(1).	[Epub ahead of print]	2019 Jan
Kodama S, Horikawa C, Fujihara K, Ishii D, Hattata M, Takeda Y, Kitazawa M, Matsubayashi Y, Shimano H, Katano K, Tanaka S, Sone H:	Relationship between intake of fruit separately from vegetables and triglycerides - A meta-analysis.	Clin Nutr ESPEN.	27	:53-58.	2018 Oct;



Araki M, Nakagawa Y, Oishi A, Han SI, Wang Y, Kumagai K, Ohno H, Mizunoe Y, Iwasaki H, Sekiya M, Matsuzaka T, Shimano H.	The Peroxisome Proliferator-Activated Receptor $\alpha$ (PPAR $\alpha$ ) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice.	Int J Mol Sci	19(7).	pii: E2148. [Epub ahead of print]	2018 Jul 23;
Furukawa S, Suzuki H, Fujihara K, Kobayashi K, Iwasaki H, Sugano Y, Yatoh S, Sekiya M, Yahagi N, Shimano H.	Malondialdehyde-modified LDL-related variables are associated with diabetic kidney disease in type 2 diabetes.	Diabetes Res Clin Pract.	141	:237-243.	2018 Jul 1:
Yamamoto Y, Takei K, Arulmozhiaraja S, Sladek V, Matsuo N, Han SI, Matsuzaka T, Sekiya M, Tomokiwa T, Shoji M, Shigeta Y, Nakagawa Y, Tomiwa H, Shimano H.	Molecular association model of PPAR $\alpha$ and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARM $\alpha$ .	Biochem Biophys Res Commun.	499(2):	239-245	2018 May;
Karasawa T, Kawashima A, Usui-Kawanishi F, Watanabe S, Kimura H, Kamata R, Shirasuna K, Kobayama Y, Sato-Tomokiwa M.	Saturated Fatty Acids Undergo Intracellular Crystallization and Activate the NLRP3 Inflammasome in Macrophages.	Arterioscler Thromb Vasc Biol.	38(4):	744-756.	2018 Apr;
Cho KI, Sakuma I, Sohn IS, Hayashi T, Shimada K, Koh KK	Best Treatment Strategies with Statins to Maximize Cardiometabolic Benefits	CIRCULATION JOURNAL	82	937-943	2019
Umegaki H, Makino T, Hayashi T, Cheng XW, Kuzuya M.	Cognitive Dysfunction in Urban-Community Dwelling Prefrail Older Subjects	JOURNAL OF NUTRITION HEALTH & AGING	22	549-555	2019

Nakayama N, Hayashi T, Miyachi M, Negi K, Watanabe K, Hirai M	Napping Improves HRV in Older Patients with Cardiovascular Risk Factors.	Western journal of nursing research	1949	9180925	2019
Komatsu T, Sakurai T, Wolska A, Amar MJ, Sakurai A, Vaisman BL, Sviridov D, Demosky S, Pryor M, Ikewaki K, Remaley AT	Apolipoprotein C-II Mimetic Peptide Promotes the Plasma Clearance of Triglyceride-Rich Lipid Emulsion and the Incorporation of Fatty Acids into Peripheral Tissues of Mice	J Nutr Metab.	In press		2019
Kameyama N, Maruyama C, Kitagawa F, Nishii K, Uenomachi K, Kitayama Y, Koga H, Chikamoto N, Kuwata Y, Torigoe J, Arimoto M, Tokumaru T, Ikewaki K, Nohara A, Otsubo Y, Yanagi K, Yoshida M, Harada-Shiba M	Dietary Intake during 56 Weeks of a Low-Fat Diet for Lomitapide Treatment in Japanese Patients with Homozygous Familial Hypercholesterolemia.	J Atheroscler Thromb.	26	72-83	2019
Ito M, Ikewaki K.	Postprandial Hyperlipemia is an Indication for Additional Risk in Sitosterolemia	J Atheroscler Thromb	25	1183-4	2018
Nohara A, Otsubo Y, Yanagi K, Yoshida M, Ikewaki K, Harada-Shiba M, Jurecka A	Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study	J Atheroscler Thromb	26	368-77	2019
Takiguchi S, Aoyori M, Yakushiji E, Nakaya K, Sasaki M, Iizuka M, Uto-Kondoh H, Terao Y, Yogo M, Komatsu T, Ogura M, Ikewaki K	Hepatic Overexpression of Endothelial Lipase Induces a Markedly Low HDL-Cholesterol but Maintains Macrophage Reverse Cholesterol Transport in Mice: Role of SR-BI/ABCA1-dependent pathways	Arterioscler Thromb Vasc Biol.	38	1454-67	2018

Sakuma I, Ikewaki K	Should Measures of High-Density Lipoprotein Function Be Added to the Low-Density Lipoprotein Cholesterol Target Level-Based Guidelines for Prevention of Atherosclerotic Disease?	Circ J	82	1251-2	2018
Mune M, Uto-Kondo H, Iteya I, Fujii Y, Ikeda S, Ikewaki K.	Vitamin E supplementation improves high-density lipoprotein and endothelial functions in end-stage kidney disease patients undergoing hemodialysis	Clin Nephrol	90	212-21	2018
Watanabe T, Nema T, Hiruta N, Murano T, Schneider WJ, Bujo H.	Lp8 is potentially associated with partial lecithin:cholesterol acyltransferase deficiency in a patient with primary biliary cirrhosis.	J Clin Lipidol.	12(5)	1157-1163	2018
Muratsu J, Kosaki M, Masuda D, Yasuga Y, Tomoyama S, Ataka K, Yagi Y, Nakagawa A, Hamada H, Fujita S, Hattori H, Ohama T, Nishida M, Hiraoka H, Matsuzawa Y, Yamashita S	Accelerated Atherogenicity in Tangier Disease	J Atheroscler Thromb.	25	1076-1085	2018
Nohara A, Ohmura H, Okazaki H, Ogura M, Kazuo Kitagawa, Koseki M, Sato K, Takasakamoto K, Yamashita S	Statement for Appropriate Clinical Use of PCSK9 Inhibitors	J Atheroscler Thromb.	25	747-750	2018
Liu J, Nishida M, Inui H, Chang J, Zhu Y, Kanino K, Matsuda H, Sairyo M, Okada T, Nakaoka H, Ohama T, Masuda D, Koseki M, Yamashita S, Sakata Y.	Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction.	J Atheroscler Thromb.		March 14th	2019

Kurano M. Ikeda H. Iso-O N. Hara M. Tsukamoto K. Yatomi Y.	Regulation of the metabolism of apolipoprotein M and sphingosine 1-phosphate by hepatic PPAR $\gamma$ activity.	Biochem J.	475(12)	2009-2024	2018
Nohara A. Ohmura H. Okazaki H. Ogura M. Kitagawa K. Koseki M. Sato K. Tsukamoto K. Yamashita S.	Statement for Appropriate Clinical Use of PCSK9 Inhibitors.	Journal of Atherosclerosis and Thrombosis	25(8)	747-750	2018
Sakamoto M. Edono N. Takahashi S. Okamura E. Uno K. Morita K. Ishikawa T. Asahi K. Iseki K. Moriyama T. Yamagata K. Tsuruya K. Fujimoto S. Narita I. Konta T. Kondo M. Kimura K. Ohashi Y. Watanabe T. Tsukamoto K.	Association between prescription and control status of dyslipidemia and hypertension among Japanese diabetic patients.	Journal of Atherosclerosis and Thrombosis	in press	in press	in press
Kurano M. Hasegawa K. Kunimi M. Hara M. Yatomi Y. Teramoto T. Tsukamoto K.	Sitosterol prevents obesity-related chronic inflammation.	BBA - Molecular and Cellular Biology of Lipids	1863(2)	191-198	2018
小山信吾, 関島良樹	脳腱黄色腫症の過去・現在・未来	The Lipid	30	52-57	2019
黒田正幸、横手幸太郎	家族性LCAT欠損症の過去・現在・未来	The Lipid	Vol.30 No.1	71-78	2019
三井田孝	LDLコレステロール(直接法)とnon-HDLコレステロール.	臨床病理	66(10)	1102-1109	2018
三井田孝	LDL-C 値の測定法 には計算式と直接法がありますが、使い分けや注意点はありますか?	検査と技術	46(7)	794-798	2018
三井田孝	LDLコレステロール直接法の実際.	日医雑誌	147(5)	980	2018
中川 嘉, 島野仁	【脂質異常症の最前線】脂質代謝におけるPPAR $\alpha$ とFGF21の役割	Medical Science Digest	44 巻14号	768-771	(2018. 12)

塚本和久	薬物の併用療法・副作用・アドヒアランス 動脈硬化性疾患予防ガイドライン2017	The Lipid	29(1)	76-81	2018
塚本和久	薬物療法 ー動脈硬化性疾患のリスク評価と管理ー	日本冠疾患学会雑誌	24(1)	32-37	2018
塚本和久	糖尿病を含めた高リスク病態における脂質管理	板橋区医師会通報	494	84-87	2018
塚本和久	治療抵抗性高コレステロール血症のくすり	スズケンファーマ	21(1)	7	2018
塚本和久	治療抵抗性高コレステロール血症とは	スズケンメディカル	21(1)	15	2018
塚本和久	動脈硬化性疾患予防ガイドライン2017年版のポイント	プラクティス	35(3)	250-256	2018
塚本和久	動脈硬化危険因子の評価	日本医師会雑誌	147(5)	965-969	2018
塚本和久	脂質異常症治療の最近の話題	帝京大学医師会報告	38	4	2018
塚本和久	マイクロソームトリグリセリド転送蛋白(MTP):機能そして治療標的として	Pharma Medica	36(10)	35-38	2018
塚本和久	MTPの生理的役割と脂質異常症 脂質異常症の最前線	Medical Science Digest	44(14)	32-35	2018
土橋一重	動脈硬化予防のための脂質異常症治療最前線 小児の脂質異常症治療	日本医師会雑誌	147	1008-1012	2018
土橋一重	生涯教育問題 「脂質異常症」に関する問題 小児(15歳未満)の動脈硬化予防について正しいのはどれか。1つ選べ。	日本医師会雑誌	147	1015	2018
土橋一重	私の処方2018 内分泌・代謝疾患の処方 家族性高コレステロール血症	小児科臨床	71	947-952	2018
土橋一重	動脈硬化性疾患予防ガイドライン2017 12.小児	The Lipid	29	98-102	2018
土橋一重	スタチンを誰にどのように使うのか? 1. 小児の家族性高コレステロール血症患者にスタチン処方を考慮すべきですか?	Modern Physician	39	159-161	2019
土橋一重	【小児疾患の診断治療基準】脂質異常症	小児内科	50	190-191	2018

男澤悠貴、塚本和久	各脂質異常症の病態と治療 —低HDLコレステロール血症	臨床と研究	96(1)	33-37	2019
高橋学, 石橋俊	【原発性高脂血症研究の過去・現在・未来】無βリポ蛋白血症の過去・現在・未来	The Lipid	30巻1号	87-93	2019
岡崎啓明	高トリグリセリド血症 動脈硬化ハイリスク遺伝子と新たな制御手段への期待	東京都医師会雑誌	71(4)	293-298	2018
岡崎啓明	高中性脂肪血症 成因、診断、治療	Medical Practice	36(1)	55-63	2019
岡崎啓明	原発性高カイロミクロン血症の過去・現在・未来	The Lipid	30(1)	58-70	2019
岡崎啓明	高中性脂肪血症の遺伝子-環境関連 apoA-V欠損症からの新知見	医学のあゆみ	268(5)	403-408	2019
小関正博	コレステロールの基礎と臨床的意義	日本栄養士会雑誌		14-17	2018
小関正博	脂質異常症のHot Topics-動脈硬化性疾患ガイドライン2017の改訂をふまえて-	西宮市医師会医学雑誌		167-173	2018
小関正博	心血管・動脈硬化性疾患～肝臓が心血管を征服する～	臨床雑誌「内科」		1315-1317	2018
小関正博	オキシステロールと動脈硬化	Heart View		65-70	2018
小関正博	LDL-C, HDL-C, TG, Non-HDL-C, TC	臨床精神医学		427-437	2018
小関正博	小腸におけるコレステロール吸収と動脈硬化	Pharma Medica		57-60	2018
村津淳、小関正博、山下静也	タンジール病の過去・現在・未来	The Lipid		79-86	2019
小関正博	重症家族性高コレステロール血症に対する根治的療法の開発 —同種脂肪組織由来多系統前駆細胞移植療法—	Medical Practice		105-108	2019
小関正博	NAFLD/NASHと動脈硬化をつなぐ分子メカニズム	医学のあゆみ 動脈硬化		369-373	2019
小関正博	NAFLD/NASHを合併した心血管疾患	Heart View		30-35	2019
小倉正恒	私の処方：家族性高コレステロール血症ヘテロ接合体	Modern Physician	38(11)	1183	2018

小倉正恒、斯波真理子	PCSK9阻害薬を用いた脂質低下治療の展望と課題	最新医学	73(6)	837-842	2018
小倉正恒、斯波真理子	疾患レビュー・治療抵抗性高コレステロール血症	スズケンメデイカル	21(1)	4-6	2018
小倉正恒、斯波真理子	疾患SUMMARY・治療抵抗性高コレステロール血症	スズケンファーマ	21(1)	6	2018
小倉正恒、斯波真理子	家族性高コレステロール血症のリスク評価と管理	日本冠疾患学会雑誌	24(1)	42-45	2018
小倉正恒	家族性高コレステロール血症の診断と治療に新ガイドラインを生かす	Mebio	35(3)	76-83	2018
小倉正恒、斯波真理子	家族性高コレステロール血症の診断と治療のコツ	CLINIC magazine	590	21-27	2018
小倉正恒、斯波真理子	家族性高コレステロール血症の分子標的	循環器専門医	27	64-71	2018
小倉正恒	<企画・編集>スタチンを使いこなす! 18の臨床 pearls	Modern Physician	39(2)	147-215	2019
小倉正恒	家族性高コレステロール血症ホモ接合体研究の過去・現在・未来	The Lipid	30(1)	38-43	2019
小倉正恒、斯波真理子	抗PCSK9核酸医薬の登場が意味するもの	医学のあゆみ「第1土曜特集 動脈硬化 UPDATE」	268(5)	438-442	2019

<p>Wilemon KA, Patel J, Aguilar-Salinas C, Ahmed C, Alkhnifawi D, Almahmeed W, Alonso R, Al-Rasadi K, Badimon L, Bernal LM, Bogsrud MP, Braun LT, Brunham L, Catapano AL, Cillikova K, Corral P, Cuevas R, Defesche JC, Descamps OS, de Ferranti S, Eisele JL, Elikir G, Folco E, Freiburger T, Fuggetta F, Gaspar IM, Gesztecs AG, Groselj U, Hamilton-Craig I, Hanauer-Mader G, <u>Harada-Shiba M</u>, Hastings G, Hovingh GK, Izar MC, Jamison A, Karlsson GN, Kayikcioglu M, Koob S, Koseki M, Lane S, Lima-Martinez MM, Lopez G, Martinez TL, Marais D, Marion L, Mata P, Maurina I, Maxwell D, Mehta R, Mensah GA, Miserez AR, Neely D, Nicholas SJ, Nohara A, Nordestgaard BG, Ose L, Pallidis A, Pang J, Payne J, Peterson AL, Popescu MP, Puri R, Ray KK, Reda A, Sampietro T, Santos RD, Schalkers I, Schreier L, Shapiro MD, Sijbrands E, Soffer D, Stefanutti C, Stoll M, Sy RG, Tamayo ML, Tilney MK, Tokgozoglu L, Tomlinson B, Vallejo-Vaz AJ, Vazquez-Cardenas A,</p>	<p>Reducing the clinical and public health burden of familial hypercholesterolemia: A global call to action.</p>	<p>JAMA cardiology. in press</p>			
---	--	----------------------------------	--	--	--



Ota-Kontani A, Hirata H, Ogura M, Tsuchiya Y, Harada-Shiba M.	Comprehensive analysis of mechanism underlying hypouricemic effect of glucosyl hesperidin.	Biochem Biophys Res Comm.	521	861-867	2020
Otani K, Tokudome T, Kamiya CA, Mao Y, Nishimura H, Hasegawa T, Arai Y, Kaneko M, Shioi G, Ishida J, Fukamizu A, Osaki T, Nagai-Okatani C, Minamoto N, Ensho T, Hino J, Murata S, Takegami M, Nishimura K, Kimamoto I, Miyazato M, Harada-Shiba M, Yoshimatsu J, Nakao K, Ikeda T, Kangawa K.	Deficiency of cardiac natriuretic peptide signaling promotes peripartum cardiomyopathy-like remodeling in the mouse heart.	Circulation	141(7)	571-588	2020
Harada-Shiba M	What arteries are affected in familial hypercholesterolemia?	Journal of Atherosclerosis Thrombosis	26	1041-1042	2019
Yamamoto T, Sawamura M, Terada C, Kashiwada K, Wada F, Yamayoshi A, Obika S, Harada-Shiba M.	Effect of modular conjugation strategy for N-acetylgalactosamine-targeted antisense oligonucleotides.	Nucleosides, Nucleotides Nucleic Acids.	16	1-10	2019
Yamamoto T, Terada C, Kashiwada K, Yamayoshi A, Harada-Shiba M, Obika S.	Synthesis of Monovalent N-Acetylgalactosamine Phosphoramidite for Liver-Targeting Oligonucleotides.	Curr Protoc Nucleic Acid Chem	78(1)	e99	2019
Hori M, Ohta N, Takahashi A, Masuda H, Isoda R, Yamamoto S, Sonoda C, Ogura M, Hosoda K, Miyamoto Y, Harada-Shiba M	Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients	Atherosclerosis	289	101-108	2019

Suzuki T, Wakao Y, Watanabe T, Hori M, Ikeda Y, Tsuchiya H, Kogure K, <u>Harada-Shiba M</u> , Fujimuro M, Kamiya H,	No enhancing effects of plasmid-specific histone acetyltransferase recruitment system on transgene expression in vivo	Nucleosides Nucleotides Nucleic Acids	38(12)	942-949	2019
Makino H, Koezuka R, Tamanaha T, Ogura M, Matsuki K, Hosoda K, <u>Harada-Shiba M</u> .	Familial Hypercholesterolemia and Lipoprotein Apheresis.	J Atheroscler Thromb	26(8)	679-687	2019
Shibata MA, <u>Harada-Shiba M</u> , Shibata E, Tosa H, Matoba Y, Hamaoka H, Iinuma M, Kondo Y.	Crude $\alpha$ -Mangostin Suppresses the Development of Atherosclerotic Lesions in Apoe-Deficient Mice by a Possible M2 Macrophage-Mediated Mechanism.	Int J Mol Sci	20(7)		2019
<u>Harada-Shiba M</u>	How much further do we need to decrease LDL cholesterol levels in heterozygous familial hypercholesterolemia?	Atherosclerosis	284	218-220	2019
Otani K, Kamiya A, Miyazaki T, Koga A, Inatomi A, <u>Harada-Shiba M</u> ,	Surface Modification with Lactadherin Augments the Attachment of Spermatozoid Microbubbles to Glycoprotein IIb/IIIa,	Ultrasound Med Biol	45(6)	1455-1465	2019
小倉正恒, 斯波真理子	家族性高コレステロール血症	動脈硬化診療のすべて日本医師会雑誌	第148巻・特別号(2)	S11-S12	2019. 10
小倉正恒	低LDLアフェレンス	動脈硬化診療のすべて日本医師会雑誌	第148巻・特別号(2)	S256-S258	2019. 10
小倉正恒, 斯波真理子	エボロクマブ・アリロクマブ, ロミタビド, ペマフィブラート	Current Therapy	Vol. 37 No. 10	78-82	2019. 10

Shimada, K., Nishitani-Yokoyama, M., Takahashi, T. & Daida, H.	Physical activity and long-term prognosis in patients with stable coronary artery disease: How often, how intense, and how long?	European journal of preventive cardiology	27	422-425	2020
Toyota, T., Morimoto, T., Iimuro, S., Iwata, H., Miyauchi, K., Inoue, T., Nakagawa, Y., Daido, H., Ozaki, Y., Sakuma, I., Furukawa, Y., Ohashi, Y., Matsuzaki, M., Nagai, R. & Kimura, T.	LDL-C levels on statins and cardiovascular event risk in stable coronary artery disease: An observation from the REAL-CAD study	European Heart Journal	40	433-433	2019
Shitara, J., Kasai, T., Konishi, H., Endo, H., Wada, H., Doi, S., Naito, R., Terashima, S., Ogita, M., Dohi, T., Okazaki, S., Miyauchi, K. & Daido, H.	Impact of Lipoprotein (a) Levels on Long-Term Outcomes in Patients With Coronary Artery Disease and Left Ventricular Systolic Dysfunction.	Circulation Journal	83	1047-1053	2019
Sai, E., Shimada, K., Yokoyama, T., Hiki, M., Iikawa, T., Ouchi, S., Aoshima, C., Kawaguchi, Y., Miyazaki, T., Fujimoto, S., Tamura, Y., Aoki, S., Watada, H., Kawamori, R. & Daida, H.	Associations between ectopic fat accumulations and cardio-metabolic factors in apparently healthy subjects: assessed by 1H-magnetic resonance spectroscopy in myocardium, liver, and skeletal muscles.	European Heart Journal-Cardiovascular Imaging	20	154-154	2019
Kitamura, K., Isoda, K., Akita, K., Miyosawa, K., Kadoguchi, T., Shimada, K. & Daida, H.	Lack of IkBNS promotes cholate-containing high-fat diet-induced inflammation and atherogenesis in low-density lipoprotein (LDL) receptor-deficient mice.	European Heart Journal	40	2495-2495	2019

<p>Itoh, H., Komuro, I., Takeuchi, M., Akasaka, T., Daida, H., Edagashira, Y., Fujita, H., Higaki, J., Hirata, K., Ishibashi, S., Isshiki, T., Ito, S., Kashiwagi, A., Kato, S., Kitagawa, K., Kitakaze, M., Kitazono, T., Kurabayashi, M., Miyachi, K., Murakami, T., Murohara, T., Node, K., Ogawa, S., Saito, Y., Seino, Y., Shigeeda, T., Shindo, S., Sugawara, M., Sugiyama, S., Terauchi, Y., Tsutsui, H., Ueshima, K., Utsunomiya, K., Yamagishi, M., Yamazaki, T., Yo, S., Yokote, K., Yoshida, K., Yoshimura</p>	<p>Achieving LDL cholesterol target levels &lt; 1.81 mmol/L may provide extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study.</p>	<p>Diabetes Obesity &amp; Metabolism</p>	<p>21</p>	<p>791-800</p>	<p>2019</p>
<p>Endo, H., Dohi, T., Miyauchi, K., Kuramitsu, S., Kato, Y., Okumura, I., Yokoyama, M., Yokoyama, T., Ando, K., Shimokazaki, S., Shimada, K., Suwa, S. &amp; Daida, H.</p>	<p>Clinical significance of non-culprit plaque regression following acute coronary syndrome: A serial intravascular ultrasound study.</p>	<p>Journal of Cardiology</p>	<p>74</p>	<p>102-108</p>	<p>2019</p>
<p>Daida, H., Dohi, T., Fukushima, Y., Ohmura, H. &amp; Miyauchi, K.</p>	<p>The Goal of Achieving Atherosclerotic Plaque Regression with Lipid-Lowering Therapy: Insights from IVUS Trials.</p>	<p>Journal of Atherosclerosis and Thrombosis</p>	<p>26</p>	<p>592-600</p>	<p>2019</p>

Daida, H.	Twenty- years History of the Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine	Juntendo Medical Journal	66	2-9	2020
Tada H, Okada H, Nomura A, Yashiro S, Nohara A, Ishigaki Y, Takamura M, Kawashiri MA	Rare and Deleterious Mutations in ABCG5/ABCG8 Genes Contribute to Mimicking and Worsening of Familial Hypercholesterolemia Phenotype	Circulation Journal	83	1917-1924	2019
Tada H, Okada H, Nomura A, Takamura M, Kawashiri MA	Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene	Lipids Health Dis	19	3	2020
Nohara A, Otsubo Y, Yanagi K, Yoshida M, Ikewaki K, Harada-Shiba M, Jurecka A:	Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study.	J Atheroscler Thromb	26	368-377	2019
Kameyama N, Maruyama C, Kitagawa F, Nishii K, Uetani K, Katayama Y, Koga H, Cehikamoto N, Kuwayama Y, Torigoe J, Arimoto M, Tokumaru T, Ikewaki K, Nohara A, Otsubo Y, Yanagi K, Yoshida M, Harada-Shiba M. :	Dietary Intake during 56 Weeks of a Low-Fat Diet for Lomitapide Treatment in Japanese Patients with Homozygous Familial Hypercholesterolemia.	J Atheroscler Thromb.	26	72-83	2019

Komatsu T, Sakurai T, Wolska A, Amar MJ, Sakurai A, Vaisman BL, Sviridov D, Demosky S, Pryor M, Ikewaki K, Remaley AT	Apolipoprotein C-II Mimetic Peptide Promotes the Plasma Clearance of Triglyceride-Rich Lipid Emulsion and the Incorporation of Fatty Acids into Peripheral Tissues of Mice	J Nutr Metab.			2019
Sasaki M, Komatsu T, Ikewaki K	Impact of Hepatic ABCA1 (ATP-Binding Cassette Transporter A1) Deletion on Reverse Cholesterol Transport: A New Clue in Solving Complex HDL (High-Density Lipoprotein) Metabolism.	Arterioscler Thromb Vasc Biol.	39(9)	1699-1701	2019
Yoshida H, Tada H, Ito K, Kishimoto Y, Yanai H, Okamura T, Ikewaki K, Inagaki K, Shoji T, Bujo H, Miida T, Yoshida M, Kuzuya M, Yamashita S.	Reference Intervals of Serum Non-Cholesterol Sterols by Gender in Healthy Japanese Individuals.	J Atheroscler Thromb.			2019
Ezaki H, Matsura T, Ayaori M, Ochi S, Mezaki Y, Masaki T, Taniwaki M, Miyake T, Sakurada M, Ikewaki K.	The fasting (13)C-glucose breath test is a more sensitive evaluation method for diagnosing hepatic insulin resistance as a cardiovascular risk factor than HOMA-IR.	Clin Chim Acta	500	20-27	2020
Kouji Kajinami, Asuka Ozaki, Yukiko Tajima, Shizuya Yamashita, Hidetoshi Arai, Tamio Teramoto	Real-world data to identify hypercholesterolemia patients on suboptimal statin therapy	J Atheroscler Thromb	26(5)	408-431	2019

<p>Koutaro Yokote, Shizuya Yamashita, Hidenori Arata, Eiichi Araki, Hideki Suganami, Shun Ishibashi, on behalf of the K-877 Study Group</p>	<p>Long-term efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor <math>\alpha</math>-modulator (SPPAR<math>\alpha</math>), in dyslipidemic patients with renal impairment</p>	<p>Int J Mol Sci</p>	<p>20(3)</p>	<p>pii: E706. doi: 10.3390/ijms20030706.</p>	<p>2019</p>
<p>Ian J. Neeland, Robert Ross, Jean-Pierre Despre, Yuji Matsuzawa, Shizuya Yamashita, Iris Shai, Jaap Seidell, Paolo Magni, Raul D. Santos, Benoit Arsenault, Adria Cuevas, Frank B. Hu, Bruce Griffin, Alberto Zambon, Philip Barter, Jean-Charles Fruchart, Robert Eckel</p>	<p>Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease:  A Joint Position of the International Atherosclerosis Society and International Chair on Cardiometabolic Risk Working Group on Visceral Obesity</p>	<p>Lancet Diabetes and Endocrinol</p>	<p>7(9)</p>	<p>715-725</p>	<p>2019</p>
<p>Takeshi Okada, Tadaharu Ohama, Kazuaki Takafuji, Kojiro Kanno, Hideoaki Matsuda, Masahiro Sairyu, Yinghong Zhu, Ayami Saito, Takuya Kobayashi, Daisaku Masuda, Masahiro Koseki, Makoto Nishida, Yasushi Sakata, Shizuya Yamashita</p>	<p>Shotgun proteomic analysis reveals proteomic alterations in HDL of patients with cholesteryl ester transfer protein deficiency</p>	<p>J Clin Lipidol</p>	<p>13(2)</p>	<p>317-325</p>	<p>2019</p>

<p>Atsushi Hirayama, Shizuya Yamashita, Andrea Ruzhiza, Hyoe Inomata, Marcoli Cyrille, Chen Lu, Andrew Hamer, Masayuki Yoshida, Akihiro Kiyosue, Tamio Teramoto</p>	<p>Long-term - treatment of evolocumab among Japanese patients: final report of the OSLER open-label extension studies (Pub-Id-074860)</p>	<p>Circ J</p>	<p>83(5)</p>	<p>971-977</p>	<p>2019</p>
<p>Jing Pang, Dick C Chan, Miao Hu, Laretta A Muller, See Kwok, Min-Ji Charng, Christopher M Florkowski, Peter George, Jie Lin, A David Marais, Hapizah M Nawawi, Lourdes E Gonzalez-Santos, Ta-Chen Su, Thanh Huong Truong, Raul D Santos, Handrea Soran, Brian Tomlinson, Shizuya Yamashita, Zanfina Ademi, Gerald F Watts</p>	<p>Comparative aspects of the care of familial hypercholesterolaemia in the "Ten Countries Study"</p>	<p>J Clin Lipidol</p>	<p>13(2)</p>	<p>287-300</p>	<p>2019</p>



<p>Jingyi Liu, Makoto Nishida, Hiroyasu Inui, Jiuyang Chang, Yinghong Zhu, Kotaro Kanono,</p> <p>Hibiki Matsuda, Masami Sairyo, Takeshi Okada, Hajime Nakaoka, Toru Ohama, Daisaku Masuda,</p> <p>Masahiro Koseki, Shizuya Yamashita, Yasushi Sakata</p>	<p>Rivaroxaban suppresses the progression of ischemic cardiomyopathy in a murine model of diet-induced myocardial infarction</p>	<p>J Atheroscler Thromb</p>	<p>26(10)</p>	<p>915-930</p>	<p>2019</p>
--	--	-----------------------------	---------------	----------------	-------------

<p>Jean-Charles Fruchart, Raul D Santos, Carlos Aguilar-Salinas, Mamasanori Aikawa, Karahamid Al Rasadi, Pierre Amarencio, Philip J Bartler, Richard Ceska, Alberto Corsini, Jean-Pierre Després, Patrick Duriez, Robert H Eckel, Marat V Ezhov, Michel Farnier, Henry N Ginsberg, Michel P Hermans, Shun Ishibashi, Fredrik Karpe, Tatsuhiro Kodama, Wolfgang Koenig, Michel Krempf, Soo Lim, Alberto J Lorenzatti, Ruth McPherson, Jesus Millan Nuñez-Cortes, Børge G Nordestgaard, Hisao Ogawa, Chris J Packard, Jorge Plutzky, Carlos I Ponte-Negretti, Aruna Pradhan, Željko Reiner, Paul M Ridker, Massimiliano Ruscica, Shaikat Sadikot, Hitoshi Shimano, Piyamitr Sritara, Jane K Stock, Ta-Chen Su, Andrey V Susekov, André Tartar, Marja-Riitta Taskinen, Alexander Tenenbaum, Lale S Tokgözoğlu, Brian Tomlinson, Anne Tybjærg-Hansen, Paul Valensi, Michal Vrablík, Walter Wahli, Gerald F Watts, Shizuya Yamashita, Koutaro Yokote, Alberto Zambon, Peter Libby</p>	<p>The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMa) paradigm: Conceptual framework and therapeutic potential. A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation</p>	<p>Cardiovascular Diabetology</p>	<p>18(1)</p>	<p>71</p>	<p>2019</p>
--	--	-----------------------------------	--------------	-----------	-------------

<p>Eiichi Araki, Shizuya Yamashita, Hidenori Arai, Koutaro Yokote, Jo Satoh, Toyoshi Inoguchi, Jiro Nakamura, Hiroshi Maegawa, Narihito Yoshioka, Yukio Tanizawa, Hirotaka Watada, Hideki Suganami, Shun Ishibashi</p>	<p>Efficacy and safety of pemafibrate in patients with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE Study</p>	<p>Diabetes Obesity Metabolism</p>	<p>21(7)</p>	<p>1737-1744</p>	<p>2019</p>
<p>Jean-Charles Fruchart, Raul D. Santos, Shizuya Yamashita, Peter Libby; International Atherosclerosis Society/R3i Foundation Consensus Panel</p>	<p>Residual vascular risk in diabetes - Will the SPPARM alpha concept hold the key?</p>	<p>Diabetes Metabolic Syndrome</p>	<p>13(4)</p>	<p>2723-2725</p>	<p>2019</p>
<p>Yasuyoshi Uchiyama, Jun Sasaki, Hidenori Arai, Koutaro Yokote, Kazumasa Harada, Yasuo Katayama, Takao Urabe, Yasufumi Uchida, Masaru Hayashi, Naoto Yokota, Hirokazu Nishida, Takatoshi Otonari, Tadayoshi Arai, Ichiro Sakuma, Kazuo Sakabe, Masayasu Yamamoto, Takashi Kobayashi, Shinichi Oikawa, Shizuya Yamashita, Hiromi Rakugi, Takumi Imai, Shiro Tanaka, Yasuo Ohashi, Masanari Kuwabara, Hideki Ito</p>	<p>Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized controlled trial</p>	<p>Circulation</p>	<p>140(12)</p>	<p>992-1003</p>	<p>2019</p>

Hiroshi Yoshida, Hayato Tada, Kumi Ito, Yoshimi Kishimoto, Hidekatsu Yanai, Hideaki Bujo, Tomonori Okamura, Katsunori Ikewaki, Tetsuo Shoji, Takashi Miida, Masayuki Yoshida, Masafumi Kuzuya, Shizuya Yamashita	Reference intervals of serum non-cholesterol sterols by gender in healthy Japanese individuals	J Atheroscler Thromb.		doi: 10.5551/jat.50187. [Epub ahead of print]	2019
Shizuya Yamashita, Hidenori Araki, Koutaro Yokote, Eiichi Araki, Mitsunori Matsushita, Toshiaki Nojima, Hideki Suganami, Shun Ishibashi	Efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor $\alpha$ modulator (SPPARM $\alpha$ ): pooled analysis of phase 2 and 3 studies in dyslipidemic patients with or without statin combination	Int J Mol Sci	20(22)	pii: E5537. doi: 10.3390/ijms20225537	2019
Shizuya Yamashita, Hidenori Araki, Hideaki Bujo, Daisaku Masuda, Tohru Ohama, Toshiyuki Ishibashi, Koji Yanagi, Yasuji Doi, Satoshi Nakagawa, Koichi Yamashiro, Kenichiro Tanabe, Toru Kita, Masunori Matsuzaki, Yasushi Saito, Masanori Fukushima, Yuji Matsuzawa, on Behalf of the PROSPECTIVE Study Group	Probuco Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE)	J Atheroscler Thromb.		doi: 10.5551/jat.55327. [Epub ahead of print]	2020

<p>Kouji Kajinami, Kazuhisa Tsukamoto, Niihari Kobayashi, Ikuo Inoue, Masashi Yamakawa, Shigeaki Suzuki, Tadanori Hamano, Hidetsugu Saito, Yoshiro Saito, Satohiro Masuda, Takeo Nakayama, Tomonori Okamura, Shizuya Yamashita, Takehiro Kagawa, Junji Kaneyama, Akira Kuriyama, Rumi Tanaka, Aya Hirata: Statin Intolerance Clinical Guidelines Working Group; The Japan Society of Hepatology, Japanese Society of Neurology, Japan Atherosclerosis Society, The Japanese Society for the Study of Xenobiotics</p>	<p>Statin intolerance clinical guide 2018</p>	<p>J Atherosclerosis Thromb</p>	<p>27(4)</p>	<p>375-396</p>	<p>2020</p>
<p>Robert Ross, Ian Neeland, Shizuya Yamashita, Irin Shai, Jacob Sesidell, Paolo Magri, Raul dos Santos, Benoit Arsault, Ada Cuevas, Frank Hu, Bruce Griffin, Alberto Zamboni, Philip Barter, Jean-Claude Fruchart, Robert Eckel, Yuji Matsuzawa, Jean-Pierre Despres</p>	<p>Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity</p>	<p>Nature Reviews Endocrinology</p>	<p>16(3)</p>	<p>177-189</p>	<p>2020</p>

Gerald F. Watts, Samuel S. Gidding, Pedro Mata, Jing Pang, David R. Sullivan, Shizuya Yamashita, Frederick J. Raal, Raul D. Santos, Kausik K. Ray	Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care	Nat Rev Cardiol		doi: 10.1038/s41569-019-0325-8. [Epub ahead of print]	2020
Daisaku Masuda, Yuko Miyata, Shingo Matsui, Shizuya Yamashita	Omega-3 fatty acid ethyl esters improve low-density lipoprotein subclasses without increasing low-density lipoprotein-cholesterol levels: A phase 4, randomized study	Atherosclerosis	292	163-170	2020
Yinghong Zhua, Toshiro Ohama, Ryota Kawase, Jiuyang Chang, Hiroyasu Inui, Kotaro Kanno, Takeshi Okada, Daisaku Masuda, Masahiro Koseki, Makoto Nishida, Yasushi Sakata, Shizuya Yamashita	Progranulin deficiency leads to enhanced cardiomyocyte hypertrophy through complement C1q-induced $\beta$ -catenin activation	J Mol Cell Cardiol	138	197-211	2020
Daisaku Masuda, Shizuya Yamashita	Postprandial glucose and triglyceride increases along with the endothelial malfunction were attenuated by the administration of SGLT2 inhibitor, empagliflozin	J Atheroscler Thromb.		doi: 10.5551/jat.ED124. [Epub ahead of print]	2020
Cesare R Sirtori, Shizuya Yamashita, Maria Franzosca Greco, Alberto Corsini, Gerald Watts, Massimiliano Ruscica	Recent advances in synthetic pharmacotherapies for dyslipidemia	Eur J Prev Cardiol.		doi: 10.1177/2047487319845314. [Epub ahead of print]	2019

Shizuya Yamashita, Daisaku Masuda, Yuji Matsuzawa	Clinical applications of a novel selective PPAR $\alpha$ modulator, pemafibrate, in dyslipidemia and metabolic diseases	J Atheroscler Thromb	26(5)	389-402	2019
Shizuya Yamashita, Daisaku Masuda, Yuji Matsuzawa	Review: Pemafibrate, a new selective PPAR $\alpha$ modulator: Drug concept and its clinical applications for dyslipidemia and metabolic diseases	Curr Atheroscler Rep	22(1):5	doi: 10.1007/s11883-020-0823-5.	2020
小倉正恒	LDLアフェレシス	動脈硬化診療のすべて日本医師会雑誌	第148巻・特別号(2)	S256-S258	2019.10
小倉正恒	家族性高コレステロール血症は正常範囲内の症例も存在すると聞きました。どのような症例で疑い、診断し、そして治療はどのようにすればよいのでしょうか？	Heart View	Vol.23 No.12	54-58	2019
小倉正恒	HDL機能は測定可能か？	Heart View	Vol.23 No.8	49-54	2019
小倉正恒	コレステロール恒常性維持に関わるABCA1と疾患・創薬	週刊 医学のあゆみ 特集「トランスポーターのすべて」	Vol.271 No.1	4-10	2019
小倉正恒	低HDL-C血症の病態と治療意義	Current Therapy	Vol.37 No.10	58-64	2019
小倉正恒	家族性高コレステロール血症～診断と治療のポイント～	Schneller	No.111	22-26	2019
小倉正恒, 斯波真理子	意外に多い家族性高コレステロール血症のキホンと食事療法のポイント	臨床栄養	第135巻 第1号	33-40	2019
小倉正恒	家族性高コレステロール血症の診断とリスク評価のためのアキレス腱エコー	超音波検査技術	Vol.44 No.4	477-485	2019

小倉正恒, 道倉雅仁, 斯波真理子	家族性高コレステロール血症超音波によるアキレス腱厚計測の有用性	検査と技術	第47巻 第10号	1174-1177	2019
小倉正恒, 斯波真理子	家族性高コレステロール血症ホモ接合体におけるアフェレシス:PCSK9阻害薬・MTP阻害薬とのすみわけ	腎と透析	Vol. 87 No. 3	475-479	2019
Mika Hori, Naotaka Ohta, Atsushi Takahashi, Hiroaki Masuda, Rieko Isoda, Suguru Yamamoto, Cheol Son, Masatsune Ogura, Kiminori Hosoda, Yoshihiro Miyamoto and Mariko Harada-Shibata	Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients	Atherosclerosis	289	101-108	2019
Daisuke Sugiyama, Tanvir Chowdhury Turin, Fahimida Yeasmin, Nahid Rumana, Mako Watanabe, Aya Higashiyama, Misasa Takegami, Yoshihiro Kokubo, Tomonori Okamura, Yoshihiro Miyamoto.	Hypercholesterolemia and Lifetime Risk of Coronary Heart Disease in the General Japanese Population : Results from the Suita Cohort Study	Journal of Atherosclerosis and Thrombosis	27(1)	60-70	2020
岡崎啓明	コレステロールとトリグリセリド 遺伝子からの新知見	New Diet Therapy	35	17-24	2019
岡崎啓明	急性膵炎とトリグリセリド	臨床栄養	135	61-67	2019
岡崎啓明	高TG血症・レムナント	日本医師会雑誌	148	S89-S93	2019
岡崎啓明	LDL受容体パスウェイ	カレントセラピー	37	1007-1007	2019
岡崎啓明	アポリポ蛋白C-IIとアポリポ蛋白A-V	臨床病理	67	1138-1148	2019



小関正博	<p>“質疑応答■代謝内分泌・糖尿病 HDL-コレステロールが著しく低い症例で注意することは？【LCAT欠損症、魚眼病、タンジール病、アポリポ蛋白質A-1欠損症等の遺伝性疾患に注意】”</p>	週刊 日本医 事新報	No. 4983	53	2019
------	--	---------------	----------	----	------

<p>Representatives of the Global Familial Hypercholesterolemia Community, Wilemon Kl A, Patel J, Aguilar-Salinas C, Ahmed CD, Alkhnif sawi M, Almahmeed W, Alonso R, Al-Rasadi K, Badimon L, Bernal LM, Bogsrud MP, Braun LT, Brunham L, Catapano AL, Cillíková K, Corral P, Cuevas R, Defesche JC, Descamps OS, de Ferranti S, Eisele JL, Elikir G, Folco E, Freiburger T, Fuggetta F, Gaspar IM, Gesztes ÁG, Grošelj U, Hamilton-Craig I, Hanauer-Mader G, Harada-Shiba M, Hastings G, Hovingh GK, Izar MC, Jamison A, Karlsson GN, Kayikçioğlu M, Koob S, Koseki M, Lane S, Lima-Martinez MM, López G, Martinez TL, Marais D, Marion L, Mata P, Maurina I, Maxwell D, Mehta R, Mensah GA, Mizeretz AR, Neely D, Nicholls SJ, Nohara A, Nordestgaard BG, Ose L, Pallidis A, Pang J, Payne J, Peterson AL, Popescu MP, Puri R, Ray KK, Reda A, Sampietro T, Santos RD, Schalkers I, Schreier L, Shapiro MD, Sijbrands E, Soffer D, Stefanutti C, Stoll M, Sy RG, Tamayo ML, Tilney MK, Tokgözoğlu L, Tomlinson B, Vallejo-Vaz AJ, Vazquez-Cárdenas A, de Luca P V, Wald DS, Watt</p>	<p>Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action.</p>	<p>JAMA Cardiol. 2020</p>	<p>Epub ahead of print</p>		<p>2020</p>
---	--	---------------------------	----------------------------	--	-------------

小関正博、岡田健志、坂田泰史	著名な低HDLコレステロール血症をきたす原発性脂質異常症の臨床的特徴と鑑別	日本内科学会雑誌	109	238	2020
Kimura M, Horie T, Baba O, Ide Y, Tsuji S, Ruiz Rodriguez R, Watanabe T, Yamasaki T, Otani C, Xu S, Miyasaka Y, Nakashima Y, Kimura T, Ono K*.	Homeobox A4 suppresses vascular remodeling by repressing YAP/TEAD transcriptional activity.	EMBO Rep.	21(4)	e48389	2020
Ono K*, Wada H, Asahara N, Inoue H, Uehara K, Fujinada J, Ogo A, Horie T, Fujita M, Shimatsu A, Hasegawa K, on behalf of the ABLE-MET Investigators.	Effects of metformin on left ventricular size and function in hypertensive patients with type 2 diabetes mellitus: results of a randomized, controlled, multicentre, Phase IV trial.	American J of Cardiovasc Drugs	Online ahead of print.		2019
Ide Y, Horie T, Saito N, Watanabe S, Otani C, Miyasaka Y, Kuwabara Y, Nishino T, Nakao T, Nishigaki M, Nishi H, Nakashima Y, Nakazeki F, Koyama S, Kimura M, Tsuji S, Rodriguez R, Xu S, Yamasaki T, Watanabe T, Yamamoto M, Yanagita M, Kimura T, Kakizuka A, Ono K*.	Cardioprotective Effects of VCP Modulator KUS121 in Murine and Porcine Models of Myocardial Infarction.	JACC Basic Transl Sci.	4(6)	701-714	2019

Koyama S, Horie T, Nishino T, Baba O, Sowa N, Miyasaka Y, Kuwabara Y, Nakao T, Nishihiga M, Nishihara H, Nakashima Y, Nakazeki F, Ide Y, Kimura M, Tsuji S, Rodriguez RR, Xu S, Yamasaki T, Otani C, Watanabe T, Nakamura T, Hasegawa K, Kimura T, Ono K*.	The identification of differential roles of microRNA-33a and -33b during atherosclerosis progression with genetically modified mice	J Am Heart Assoc	8(13)	e012609	2019
Sakamoto M. Edo N. Takahashi S. Okamura E. Uno K. Morita K. Ishikawa T. Asahi K. Iseki K. Moriyama T. Yamagata K. Tsuruya K. Fujimoto S. Narita I. Konta T. Kondo M. Kimura K. Ohashi Y. Watanabe T.	Association between prescription and control status of dyslipidemia and hypertension among Japanese diabetic patients.	Journal of Atherosclerosis and Thrombosis	26	805-820	2019
Kajinami K. Tsukamoto K. Kobayashi N. Inoue I. Yamakawa M. Suzuki S. Hamano T. Saito H. Saito Y. Masuda T. Nakayama T. Okamura T. Yamashita S. Kagawa T. Kaneyama J. Kuriyama A. Tanaka R. Hirata A. Statin Intolerance Clinical Guide 2018	Statin Intolerance Clinical Guide 2018	Journal of Atherosclerosis and Thrombosis	27	375-396	2020
Kurano M. Kano K. Hara M. Tsukamoto K. Aoki J. Yatomi Y.	Regulation of plasma glycerol-lysophospholipid levels by lipoprotein metabolism.	Biochem J.	476	3565-3581	2019
磯尾直之、塚本和久	スタチン治療のエビデンス	カレントセラピー	37	943-947	2019
磯尾直之、塚本和久	スタチン a) 薬効	日本医師会雑誌	148 (特別号2)	222-225	2019

塚本和久	冠動脈疾患絶対リスク評価および個別化脂質管理目標値設定のための吹田スコア	総合健診	46	480-488	2019
磯尾直之、塚本和久	中性脂肪 (TG) はどこまで下げる?	循環器ジャーナル	67	600-607	2019
後藤田貴也	栄養・代謝とエイジング	Ageing Science	12	56-59	2019
Todate Y, Uwano I, Yashiro S, Chida A, Hasegawa Y, Oda T, Nagasawa K, Honma H, Sasaki M, Ishigaki Y	High Prevalence of Cerebral Small Vessel Disease on 7T Magnetic Resonance Imaging in Familial Hypercholesterolemia.	J Atheroscler Thromb.	26(12)	1045-1053	2019
Tada H, Okada H, Nomura A, Yashiro S, Nohara A, Ishigaki Y, Takamura M, Kawashiri MA.	Rare and Deleterious Mutations in ABCG5/ABCG8 Genes Contribute to Mimicking and Worsening of Familial Hypercholesterolemia Phenotype.	Circ J.	83(9)	1917-1924.	2019
Sawada T, Kido J, Yoshida S, Sugawara K, Momosaki K, Inoue T, Tajima G, Sawada H, Mastumoto S, Endo F, Hirose S, Nakamura K.	Newborn screening for Fabry disease in the western region of Japan.	Mol Genet Metab Rep.	22	100562	2020
Watanabe S, Kido J, Ogata M, Nakamura K, Mizukami T	Hyperglycemic hyperosmolar state in an adolescent with type 1 diabetes mellitus.	Endocrinol Diabetes Metab Case Rep.	18-0131	doi: 10.1530/EDM-18-0131	2019
Momosaki K, Kido J, Yoshida S, Sugawara K, Miyamoto T, Inoue T, Okumiya T, Matsumoto S, Endo F, Hirose S, Nakamura K	Newborn screening for Pompe disease in Japan: report and literature review of mutations in the GAA gene in Japanese and Asian patients.	J Hum Genet.	64(8)	741-755	2019
Kido J, Matsumoto S, Sawada T, Endo F, Nakamura K	Rhabdomyolysis in organic acidemia patients manifesting with metabolic decompensation.	Hemodial Int.	23	E115-E119	2019

Mehta A, Kuter DJ, Salek SS, Belmatoug N, Bembi B, Bright J, Vom Dahl S, Deodato F, Di Rocco M, Göker-Alpan O, Hughes DA, Lukina EA, Machaczka M, Mengel E, Nagral A, Nakamura K, Narita A, Oliveri B, Pastores G, Pérez-López J, Ramaswami U, Schwartz IV, Szer J, Weinreb NJ,	Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative.	Intern Med J	49(5)	578-591	2019
Matsumoto S, Häberle J, Kido J, Mitsubuchi H, Endo F, Nakamura K.	Urea cycle disorders-update.	J Hum Genet.	64(9)	833-847	2019
Suzuki Y, Kido J, Matsumoto S, Shimizu K, Nakamura K	Associations among amino acid, lipid, and glucose metabolic profiles in childhood obesity.	BMC Pediatr.	19(1)	273	2019
Matsuzaka T, Shimano H.	New perspective on type 2 diabetes, dyslipidemia and non-alcoholic fatty liver disease.	J Diabetes Investig.	11(3)	532-534.	2020
Satoh A, Han SI, Araki M, Nakagawa Y, Ohno H, Mizunoe Y, Kumagai K, Murayama Y, Osaki Y, Iwasaki H, Sekiya M, Konishi M, Itoh N, Matsuzaka T, Sone H, Shimano H.	CREBH Improves Diet-Induced Obesity, Insulin Resistance, and Metabolic Disturbances by FGF21-Dependent and FGF21-Independent Mechanisms	iScience.	;23(3):1009-30.		2020

Manda CM, Hokimoto T, Okura T, Iida T, Soda H, Shimano H, Wagatsuma Y.	Handgrip Strength Predicts New Prediabetes Cases Among Adults: A Prospective Cohort Study	Prev Med Rep.	17:101056.	-	2020
Kawasaki M, Kambayashi A, Yamamoto Y, Arulmozhiraja S, Ito S, Nakagawa Y, Tokiwa H, Nakano S, Shimano H.	Elucidation of Molecular Mechanism of a Selective PPAR $\alpha$ Modulator, Pemafibrate, Through Combinational Approaches of X-ray Crystallography, Thermodynamic Analysis, and First-Principle Calculations	Int J Mol Sci.	6;21(1):361.	-	2020
Matsuzaka T, Kubota M, Koyasu S, Yamamoto Y, Motomura K, Arulmozhiaraja S, Ohno H, Sharma R, Shimura T, Okajima Y, Han SI, Aita Y, Mizunoe Y, Osaki Y, Iwasaki H, Yatah S, Suzuki H, Sone H, Takeuchi Y, Yahagi N, Miyamoto T, Sekiya M, Nakagawa Y, Ema M, Takahashi S, Tokiwa H, Shimano H.	Hepatocyte ELOVL Fatty Acid Elongase 6 Deficiency Terminates Ceramide Acyl-Chain Length and Hepatic Insulin Sensitivity in Mice	Hepatology.	71(5):	1609-1625.	2020
Fruchart JC, Santos RD, Yamashita S, Libby P; International Atherosclerosis Society/R3i Foundation Consensus Panel.	Residual Vascular Risk in Diabetes - Will the SPPARM Alpha Concept Hold the Key?	Diabetes Metab Syndr	13(4):	2723-2725.	2019

<p>Mizunoe Y, Kobayashi M, Tagawa R, Nakagawa Y, Shimano H, Higami Y.</p>	<p>Association Between Lysosomal Dysfunction and Obesity-Related Pathology: A Key Knowledge to Prevent Metabolic Syndrome</p>	<p>Int J Mol Sci.</p>	<p>20(15):3688.</p>	<p>-</p>	<p>2019</p>
<p>Fruchart JC, Santos RD, Aguilar-Salinas C, Aikawa M, Al Rasadi K, Amarencu P, Barter PJ, Ceska R, Corsini A, DeCrespo JP, Duriez P, Eckel RH, Ezkandrov MV, Farnier M, Ginsberg HN, Hermans MP, Ishibashi S, Karpe F, Kodama T, Koettgen W, Krempf M, Lim S, Lorenzatti AJ, McPherson R, Nuñez-Cortés JM, Nordestgaard BG, Ogawa H, Packard CJ, Plutzky J, Ponte-Negretti CI, Pradhan A, Ray KK, Reiner Ž, Ridker PM, Ruscica M, Sadikot S, Shimano H, Sritara P, Stock JK, Su TC, Susekov AV, Tartar A, Taskinen MR, Tenenbaum A, Tokgözoğlu LS, Tomlinson B, Tybjaerg-Hansen A, Valensi P, Vrablik M, Wahli W, Watts GF, Yamashita S, Yokote K, Zambon A, Libby P.</p>	<p>The Selective Peroxisome Proliferator-Activated Receptor Alpha Modulator (SPPARM<math>\alpha</math>) Paradigm: Conceptual Framework and Therapeutic Potential : A Consensus Statement From the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation</p>	<p>Cardiovasc Diabetol.</p>	<p>18(1):71.</p>	<p>-</p>	<p>2019</p>



稲垣恭子	糖尿病におけるリポ蛋白代謝異常とその治療	医学のあゆみ	268	410-414	2019
Yoshida H, Tada H, Ito K, Kishimoto Y, Yanai H, Okamura T, Ikewaki K, Inagaki K, Shoji T, Bujo H, Miida T, Yoshida M, Kuzuya M, Yamashita S.	Reference Intervals of Serum Non-Cholesterol Sterols by Gender in Healthy Japanese Individuals.	J Atheroscler Thromb	1;27(5)	409-417	2019
小倉正恒	家族性高コレステロール血症ホモ接合体の管理	糖尿病・内分泌代謝科	51(2)	157 - 163	2020
小倉正恒	もっともっとくわしく知りたい!イラストでわかる脂質・脂肪酸・コレステロールのふしぎ 続発性脂質異常症	Nutrition Care	13(4)	335 - 338	2020
小倉正恒	ω3脂肪酸と動脈硬化予防	BIO INDUSTRY	37(10)	63 - 72	2020
多田隼人, 岡田寛史, 高村雅之, 山尻剛照	遺伝子研究からみた脂質異常症	糖尿病・内分泌代謝科	51(2)	85-91	2020
土橋一重	小児疾患の薬物治療ガイドライン総まとめ	月刊薬事	増刊号	1425-1431	2020
土橋一重	綜説 小児家族性高コレステロール血症診療ガイド	小児科	61	878-886	2020
土橋一重	小児期における肥満・脂質異常症の治療	診断と治療	108	1381-1385	2020
山下静也	LDLコレステロールが高い状態を放置しないで	日医ニュース	令和2年8月5日号	健康ふらざ No. 533:1	2020
岡崎啓明	糖尿病患者の脂質異常症	【糖尿病エキスパートブック 食事療法・栄養指導に活かす最新情報】「臨床栄養」	136(6)	853-858	2020

岡崎啓明	PCSK9阻害薬を処方すべき患者とは	【いま知っておきたい！内科最新トピックス】内科	126(3)	2020	617-620
岡崎啓明	PCSK9阻害薬	診断と治療	108(10)	2020	
稲垣恭子	Lp(a)と動脈硬化	Medical View Point	41(8)	2020	4
稲垣恭子	MTP 阻害薬 (microsomal triglyceride transfer protein inhibitor) :ロミタピド	糖尿病・内分泌代謝科	51 (2)	2020	151-156
野原 淳	【脂質異常症と動脈硬化update】「PCSK9阻害薬」	糖尿病・内分泌代謝科	51 (2)	2020	129-135
野原 淳	動脈硬化予防のための肥満・脂質異常症診療戦略 肥満・脂質異常の病態・診断基準	診断と治療	108(10)	2020	1325-1333
小倉正恒	【脂質がつなぐもの：生物工学的脂質研究が導く新しい学際研究と産業(後編)】HDLはまだ死んでいない	生物工学会誌	98(10)	536 - 539	2020
小倉正恒	令和時代の脂質異常症の診断と治療update 動脈硬化予防におけるHDL-C値の考え方	Medical View Point	41(8)	2	2020
多田隼人、高村雅之	脂質異常症 特集/ゲノム医療と分子標的治療の最新情報	臨床と研究	97(4)	51-57	2020

多田隼人、高村雅之	遺伝子研究・臨床研究から考察するスタチン残余リスクにおける高中性脂肪血症治療の意義	日本臨床生理学雑誌	Vol. 50 No. 3	101-107	2020
岡崎啓明	血中脂質研究の今 環境と遺伝子 高TG血症はなぜ増悪するのか?	脂質生化学研究	62	8-11	2020
岡崎啓明	原発性高カイロミクロン血症	新薬と臨床	70(1)		2021
稲葉雄二, 関島良樹	小児期から認知されるべき疾患 脳腱黄色腫症	日本小児科学会雑誌	124(10)	1475-1483	2020
塚本和久	脳心血管病予防に関する包括的リスク管理チャート2019年版について	総合健診	47(5)	564-573	2020
男澤悠貴、塚本和久	脂質異常症の診断基準・鑑別診断	診断と治療	108(10)	1335-1340	2020
山下静也	特集：動脈硬化予防のための肥満・脂質異常症診療戦略 13. 脂質異常症の薬物療法：治療開始のタイミングと管理目標値	診断と治療	108(10)	1353-1361	2020
山下静也	脂質異常症の検査と治療の最前線	日本内科学会雑誌			

小関正博	あなたも名医！Jmed70 評価・処方の“いま”を押さえる 見直し！脂質異常症	日本医事新報社	隔月号70号	77-82	2020
山下静也、増田大作、小倉正恒、岡村智教、神崎恒一、梶波康二、佐藤加代子、塚本和久、土橋一重、秋下雅弘、浅田祐士郎、荒井秀典、石橋 俊、江頭健輔、葛谷雅文、斯波真理子、島野 仁、平田健一、横手幸太郎、木下 誠、横出正之、吉田雅幸	高脂血症治療薬開発のガイドライン	平成31年度厚生労働行政推進調査事業費補助金（医薬品・医療機器等レギュラトリーサイエンス政策研究事業）「脂質異常症改善薬の臨床評価に関するガイドラインの合理化・国際統合化に向けた研究」（研究代表者：山下静也）2020年度報告書	in press	in press	
山下静也、花田浩之、増田大作、倭正也、中尾彰太、松岡哲也	りんくう総合医療センターにおけるCOVID-19対応—自己完結型確定診断システムの構築と院内感染防止対策—	日本冠疾患学会雑誌	2	19-28	2020
山下静也	2020年度日本内科学会生涯教育講演会 Cセッション 脂質異常症の検査と治療の最前線	日本内科学会雑誌	110(3)	546-555	2021
山下静也	特集 ドクターにお聞きしました コレステロールと中性脂肪	すこぶる	第217号 冬号2021	6-11	2021
山下静也	Ⅲ章. 代謝疾患 1. 脂質代謝異常 1) リポ蛋白代謝とその調節機構	生涯教育シリーズ101 『日本医師会雑誌』特別号	(2)	in press	2021

Harada-Shiba M, Ali S, Gipe D, A, Gasparino E, Son V, Zhang Y, Pordy R, Capapano AL	A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects	Atherosclerosis	314	33-40	2020
Yamashita S, Masuda D, Akishita M, Arai H, Asada Y, Dobashi K, Egashira K, Harada-Shiba M, Hirata K, Ishibashi S, Kajinami K, Kinoshita M, Kozaki K, Kuzuya M, Ogura M, Okamura T, Sato K, Shimano H, Tsukamoto K, Yokode M, Yokote K, Yoshida M	Guidelines on the Clinical Evaluation of Medicinal Products for Treatment of Dyslipidemia	J Atherosclerosis Thromb	27(11)	1246-1254	2020
Blom DJ, Harada-Shiba M, Rubba P, Gaudet D, Kastelein J J.P, Charng M-J, Pordy R, Donahue S, Ali S, Dong Y, Khilla N, Baccara-Dinet M, Rosenson R	Efficacy and safety of Alirocumab in adults with homozygous familial hypercholesterolemia The ODYSSEY HoFH trial	Journal of the American College of Cardiology	76(2)	131-142	2020
Hori M, Takahashi A, Son C, Ogura M, Harada-Shiba M	The first Japanese cases of familial hypercholesterolemia due to a known pathogenic APOB gene variant, c.10580 G>A: p.(Arg3527Gln)	J Clin Lipidol	14(4)	482-486	2020
Tada H, Hori M, Nomura A, Hosomichi K, Nohara A, Kawashiri M, Harada-Shiba M	A catalog of the pathogenic mutations of LDL receptor gene in Japanese familial hypercholesterolemia	J Clin Lipidol	14(3)	346-351	2020

<p>Hori M, Takahashi A, Son C, Ogura M, Harada-Shiba M</p>	<p>The benign c.344G &gt; A: p.(Arg115His) variant in the LDLR gene interpreted from a pedigree-based genetic analysis of familial hypercholesterolemia</p>	<p>Lipids Health Dis</p>	<p>19(1)</p>	<p>62</p>	<p>2020</p>
--	---	--------------------------	--------------	-----------	-------------

<p>Wilemon KA, Patel J, Aguilar-Salinas C, Ahmed CD, Alkhnifawi M, Almahmeed W, Alonso R, Al-Rasadi K, Badimon L, Bernal LM, Bogsrud MP, Braun LT, Brunham L, Catapano AL, Cillikova K, Corral P, Cuevas R, Defesche JC, Descamps OS, Ferranti S, Eisele JL, Elikir G, Folco E, Freiburger T, Fuggetta F, Gasparim, Gesztes AG, Groselj U, Hamilton-Craig I, Hanauer-Mader G, <u>Harada-Shiba M</u>, Hastings G, Hovingh GK, Izar MC, Jamison A, Karlsson GN, Kayikcioglu M, Koob S, <u>Koski M</u>, Lane S, Lima-Martinez MM, Lopez G, Martinez TL, Marais D, Marion L, Mata P, Maurina I, Maxwell D, Mehta R, Mensah GA, Miserez AR, Neely D, Nicholls SJ, <u>Nohara A</u>, Nordestgaard BG, Ose L, Pallidis A, Pang J, Payne J, Peterson AL, Popescu MP, Puri R, Ray KK, Reda A, Sampietro T, Santos RD, Schalkers I, Schreier L, Shapiro MD, Sijbrands E, Soffer D, Stefanutti C, Stoll M, Sy RG, Tamayo ML, Tilney MK, Tokgozoglul L, Tomlinson B, Vallejo-Vaz AJ, Vazquez-Cardenas A, de Luca PV, Wald DS, Watts GF, Wenger NK, Wolf M, Wood D, Zegerius A, Gaziano TA, Gidding SS</p>	<p>Reducing the clinical and public health burden of familial hypercholesterolemia: A global call to action</p>	<p>JAMA cardiol</p>	<p>5(2)</p>	<p>217-229</p>	<p>2020</p>
--	---	---------------------	-------------	----------------	-------------

<p>Tada H, Okada H, Nomura A, Nomura A, Takamura M, Kawashiri MA</p>	<p>A Healthy Family of Familial Hypobetalipoproteinemia Caused by a Protein-truncating Variant in the PCSK9 Gene</p>	<p>Intern Med</p>	<p>59(6)</p>	<p>783-787</p>	<p>2020</p>
<p>Tada H, Usui S, Sakata K, Takamura M, Kawashiri MA</p>	<p>Low-Density Lipoprotein Cholesterol Level cannot be too Low: Considerations from Clinical Trials, Human Genetics, and Biology</p>	<p>J Atheroscler Thromb</p>	<p>1;27(6)</p>	<p>489-498</p>	<p>2020</p>



<p>Tada H, Okada H, Yoshida S, Shimojima M, Nomura A, Tsuda T, Mori M, Takashima SI, Kato T, Usui S, Sakata K, Hayashi K, Fujino N, Inazu A, Takahara S, Imai Y, Matsubara T, <u>Nohara A</u>, Miwa K, Namura M, Terai H, Yoshida T, Araki T, Minamoto M, Aburao T, Ito Y, Nakanishi C, Kawasaki S, Todo Y, Koizumi J, Kitayama Y, Matsumoto H, Shintaku H, Hodatsu A, Ino H, Higashikata T, Takata M, Misawa K, Yamaguchi M, Noji Y, Osato K, Mabuchi T, Ichise T, Kaku B, Katsuda S, Fujimoto M, Uchiyama K, Fujioka K, Nakahashi T, Nozue T, Michishita I, Usuda K, Ohtowa K, Okeie K, Hirota S, Aburadani I, Kurokawa K, Takatori O, Hondo S, Oda H, Takata S, Murai H, Kinoshita M, Nagai H, Sekiguchi Y, Sakagami S, Omi W, Fujita C, Katsuki T, Ootsuji H, Igarashi A, Nakano M, Okura S, Maeno K, Mitamura Y, Sugimoto N, Yamamoto M, Akao H, Kajinami K, Takamura M, <u>Kawashiri MA</u></p>	<p>Hokuriku-plus familial hypercholesterolemia registry study: rationale and study design</p>	<p>BMJ Open</p>	<p>10;10(9)</p>	<p>e038623</p>	<p>2020</p>
<p>Tada H, Okada H, Nomura A, <u>Nohara A</u>, Usui S, Sakata K, Takamura M, <u>Kawashiri MA</u></p>	<p>A reassessment of the Japanese clinical diagnostic criteria of familial hypercholesterolemia in a hospital-based cohort using comprehensive genetic analysis</p>	<p>Pract Lab Med</p>		<p>19;22:e00180</p>	<p>2020</p>

Tada H, Shibaya ma J, Nishikawa T, Okada H, No mura A, Usui S, Sakata K, Hash iba A, Inazu A, Takamura M, Ka washiri MA	Prevalence, self-awareness, and LDL cholesterol levels among patients highly suspected as familial hypercholesterolemia in a Japanese community	Pract Lab Me		19;22:e00181	2020
Philip J Barte r, Shizuya Yam ashita, Ulrich Laufs, Alvaro J Ruiz, Rody Sy, Mark David G. F ang, Emanuela F olco, Peter Lib by, Yuji Matsuz awa, Raul D. Sa ntos	Gaps in beliefs and practice in dyslipidaemia management in Japan, Germany, Colombia and the Philippines: insights from a web-based physician survey	Lipids in Health and Disease	19	131	2020
Gerald F. Watt s, Samuel S. Gi dding, Pedro Ma ta, Jing Pang, David R. Sullivan, Shizuya Yam ashita, Frederi ck J. Raal, Raul D. Santos, Ka usik K. Ray	Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care	Nat Rev Cardiol	17(6)	360-377	2020
Yoshida H, Tada H, Ito K, Kish imoto Y, Yanai H, Okamura T, I kewaki K, Inaga ki K, Shoji T, Bujo H, Miida T, Yoshida M, K uzuya M, Yamash ita S	Reference Intervals of Serum Non-Cholesterol Sterols by Gender in Healthy Japanese Individuals	J Atheroscler Thromb	1;27(5)	409-417	2020
Yamashita S, Ar ai H, Bujo H, M asuda D, Ohama T, Ishibashi T, Yanagi K, Doi Y, Nakagawa S, Yamashiro K, Ta nabe K, Kita T, Matsuzaki M, S aito Y, Fukushi ma M, Matsuzawa Y: PROSPECTIVE Study Group	Probuocol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE)	J Atheroscler Thromb		doi: 10.5551/jat.55327. [Epub ahead of print]	2020

Suwa S, Ogita M, Takahashi N, Wada H, Dohi T, Kasai T, <u>Okazaki S</u> , Shimada K, Miyauchi K, <u>Bujo H</u> , <u>Daida H</u>	Impact of LR11 as Residual Risk on Long-Term Clinical Outcomes in Patients with Coronary Artery Disease Treated with Statins after First Percutaneous Coronary Intervention	Int Heart J	30;61(3)	470-475	2020
Shimizu M, Miyazaki T, Takagi A, Sugita Y, Ouchi S, Aikawa T, Shiozawa T, Hiki M, Takahashi S, Hiki M, Shimada K, <u>Daida H</u>	Low coenzyme Q10 levels in patients with acute cardiovascular disease are associated with long-term mortality	Heart Vessel		doi: 10.1007/s00380-020-01698-7. Online ahead of print. PMID: 32939561	2020
Kamo Y, Fujimoto S, Aoshima C, Kawaguchi YO, Nozaki Y, Kudo A, Takahashi D, Takamura K, Hiki M, Tomizawa N, Kumamaru KK, Aoki S, <u>Daida H</u> .	A study on the prevalence, distribution and related factors of heart valve calcification using coronary CT angiography	Int J Cardiovasc	1;29:10057	doi: 10.1016/j.ijcha. PMID: 32642552	2020
Todate Y, Uwano I, Yashiro S, Chida A, Hasegawa Y, Oda T, Nagasawa K, Honma H, Sasaki M, <u>Ishigaki Y</u>	High Prevalence of Cerebral Small Vessel Disease on 7T Magnetic Resonance Imaging in Familial Hypercholesterolemia	J Atheroscler Thromb	26(12)	1045-1053	2019
Tada H, Okada H, Nomura A, Yashiro S, <u>Nohara A</u> , <u>Ishigaki Y</u> , Takamura M, <u>Kawashiri MA</u>	Rare and Deleterious Mutations in ABCG5/ABCG8 Genes Contribute to Mimicking and Worsening of Familial Hypercholesterolemia Phenotype	Circ J	83(9)	1917-1924	2019

Jun Kido, Hironobu Inoue, Hiroshi Shimotsu, Yutaka Yoshida, Yosuke Suzuki, <u>Kimitoshi Nakamura</u> , Fumio Endo, Shirou Matsumoto	Effect of L-Carnitine on Amino Acid Metabolism in Elderly Patients Undergoing Regular Hemodialysis	Critical Care Nephrology - Research Article	49	614-621 DOI: 10.1159/000505609	2020
Yamamuro D, Yamazaki H, Osuga JI, Okada K, Wakabayashi T, Takei A, Takei S, Takahashi M, Nagashima S, Holleboom AG, Kuroda M, <u>Bujo H</u> , <u>Ishibashi S</u>	Esterification of $\beta$ -hydroxycholesterol and other oxysterols in human plasma occurs independently of LCAT	J Lipid Res	61(9)	1287-1299	2020
Hayato Tada, Akihiro Nomura, Masatsune Ogura, <u>Kazushige Dobashi</u> , <u>Kyoko Inagaki</u> , <u>Yasushi Ishigaki</u> , <u>Kimitoshi Nakamura</u> , <u>Katsunori Ikewaki</u> , <u>Kazuhisa Tsukamoto</u> , <u>Shizuya Yamashita</u> , <u>Masaaki Kawashiri</u> , <u>Mariko Harada-Shiba</u>	Diagnosis and management of sitosterolemia 2020	J Atherosclerosis Thromb			
Kojima N, <u>Tada H</u> , Usui S, Sakata K, Hayashi K, <u>Nohara A</u> , Inazu A, Takamura M, <u>Kawashiri MA</u>	Serum sitosterol level predicting ABCG5 or ABCG8 genetic mutations	Clin Chim Acta	507	11-16	2020

Nomura A, Emdin CA, Won HH, Peloso GM, Natarajan P, Ardissino D, Danesh J, Schunkert H, Correa A, Bown MJ, Samani NJ, Erdmann J, McPherson R, Watkins H, Saleheen D, Elosua R, <u>Kawashiri MA</u> , <u>Tada H</u> , Gupta N, Shah SH, Rader DJ, Gabriel S, Kherran AV, Kathiresan S	Heterozygous ABCG5 Gene Deficiency and Risk of Coronary Artery Disease	Circ Genom Precis Med	13(5)	417-423	2020
<u>Tada H</u> , Takamura M, <u>Kawashiri MA</u>	Genomics of hypertriglyceridemia	Adv Clin Chem	97	141-169	2020
Chie Iitake, Daisaku Masuda, Masahiro Koseki, <u>Shizuya Yamashita</u>	Marked effects of novel selective peroxisome proliferator-activated receptor $\alpha$ modulator, pemafibrate in severe hypertriglyceridemia	Cardiovasc Diabetol	19	201	2020
<u>Shizuya Yamashita</u> , Mitsuyo Okazaki, Takeshi Okada, Daisaku Masuda, <u>Koutaro Yokote</u> , Hidenori Arai, Eiichi Araki, <u>Shun Ishibashi</u>	Distinct differences in lipoprotein particle number evaluation between GP-HPLC and NMR: analysis in dyslipidemic patients administered a selective PPAR $\alpha$ modulator, pemafibrate	J Atheroscler Thromb			
<u>Shizuya Yamashita</u> , Daisaku Masuda, Yuji Matsuzawa	Review: Pemafibrate, a new selective PPAR $\alpha$ modulator: Drug concept and its clinical applications for dyslipidemia and metabolic diseases	Curr Atheroscler Rep	22(1)	doi: 10.1007/s11883-020-0823-5	2020

Konishi H, Miyauchi K, Onishi A, Suzuki S, Fujimoto D, Shitara J, Endo H, Wada H, Doi S, Naito R, Ogita M, Dohi T, Kasai T, <u>Daida H</u>	Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor $\alpha$ modulator (SPPARM $\alpha$ ), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury	PLoS One	15(11)	e0241195. doi: 10.1371/journal.pone.0241195. eCollection 2020. PMID: 33201888	2020
Sai E, Shimada K, Aikawa T, Aoshima C, Takamura K, Hiki M, Yokoyama T, Miyazaki T, Fujimoto S, Konishi H, Hirano KI, <u>Daida H</u> , <u>Minamino T</u>	Triglyceride Deposits in Cardiomyopathy with Massive Myocardial Triglyceride which was Proven Using Proton-magnetic Resonance Spectroscopy	Intern Med		doi: 10.2169/INTERNALMEDICINE.6126-20. Online ahead of print. PMID: 33162485	2020
Takashi Yamamoto, <u>Takanari Gotoda</u>	Polygenic Architecture of Common Severe Hypertriglyceridemia	J Atheroscler Thromb	27(12)	1255-1256. doi: 10.5551/jat.ED133. Epub 2020 Jun 4. PMID: 32493883 DOI: 10.5551/jat.ED133	2020
Kawasaki M, Kambe A, Yamamoto Y, Arulmozhiraja S, Ito S, Nakagawa Y, Tokiwa H, Nakano S, Shimano H	Elucidation of Molecular Mechanism of a Selective PPAR $\alpha$ Modulator, Pemafibrate, through Combination of X-ray Crystallography, Thermodynamic Analysis, and First-Principle Calculations	Int J Mol Sci	21(1): 361	doi: 10.3390/ijms21010361. PMID: 31935812; PMCID: PMC6981837	2020
Yinghong Zhu, Tadaharu Ohama, Ryota Kawase, Jiuyang Chang, Hiroyasu Inui, Kotaro Kanno, Takeshi Okada, Daisaku Masuda, <u>Masahiro Koseki</u> , Makoto Nishida, Yasushi Sakata, <u>Shizuya Yamashita</u>	Progranulin deficiency leads to enhanced age-related cardiac hypertrophy through complement C1q-induced $\beta$ -catenin activation	J Mol Cell Cardiol	138	197-211	2020

<p>Kouji Kajinami, Kazuhisa Tsukamoto, Niihari Koba, Ikuo Inoue, Masashi Yamakawa, Shigeaki Suzuki, Tadanori Hamano, Hidetsugu Saito, Yoshiro Saito, Satoshi Masuda, Takeo Nakayama, Tomonori Okamura, Shizuya Yamashita, Takehiro Kagawa, Junji Kaneyama, Akira Kuriyama, Rumi Tanaka, Aya Hirata: Statin Intolerance Clinical Guidelines Working Group; The Japan Society of Hepatology, Japanese Society of Neurology, Japan Atherosclerosis Society, The Japanese Society for the Study of Xenobiotics</p>	<p>Statin intolerance clinical guide 2018</p>	<p>J Atherosclerosis Thromb</p>	<p>27(4)</p>	<p>375-396 doi: 10.5551/jat.50948</p>	<p>2020</p>
<p>Robert Ross, Ian Neeland, Shizuya Yamashita, Iris Shai, Jacob Seidell, Paolo Magni, Raul dos Santos, Benoit Arsenault, Ada Cuevas, Frank Hu, Bruce Griffin, Alberto Zambon, Philip Barter, Jean-Claude Fruchart, Robert Eckel, Yuji Matsuzawa, Jean-Pierre Despres</p>	<p>Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCOR Working Group on Visceral Obesity</p>	<p>Nature Reviews Endocrinology</p>	<p>16(3)</p>	<p>177-189</p>	<p>2020</p>

<p>Daisaku Masuda, Arihiro Kiyosue, Atsushi Hirayama, Junichiro Shimauchi, J. Antonio G. López, Kazumasa Miyawaki, <u>Shizuya Yamashita</u></p>	<p>Evolocumab effects on lipoproteins, measured by high-performance liquid chromatography</p>	<p>J Atherosclerosis Thromb</p>	<p>27(11)</p>	<p>1183-1207</p>	<p>2020</p>
<p>A Report from the Asian Pacific Society of Atherosclerosis and Vascular Disease</p> <p>Asia Pacific Peripheral Artery Disease Consensus Statement</p> <p>Project Committee: Maria Teresa B. Abola, Jonathan Golledge, Tetsuro Miyata, Seung-Woon Rha, Bryan Yan, Timothy, Marie Simonette Gannon, Salim Harris, Pankaj Kumar, Rama Krishna Pinjala, Peter Robless, Hiroyoshi Yokoi, Raden Suhartono, Jiang Zhisheng, Elaine Alajar, April Bermudez delos Santos, Elmer Jasper Llanes, Marjorie Obrado, Noemi Pestano, Felix Eduardo Punzalan C, Bernadette Tumanan.</p> <p>Steering Committee: Edward Janus, Rody G. Sy, Fatima R. Collado, Florimond A. Garcia, <u>Shizuya Yamashita</u></p>	<p>Asia Pacific Consensus Statement on the management of peripheral artery disease</p>	<p>J Atherosclerosis Thromb</p>			



<u>Shizuya Yamashita</u> , Daisaku Masuda, Yuji Matsuzawa	Editorial: New horizons for an old, mysterious drug probucol	J Atherosclerosis Thromb			
Daisaku Masuda, Yuko Miyata, Shingo Matsui, <u>Shizuya Yamashita</u>	Omega-3 fatty acid ethyl esters improve low-density lipoprotein subclasses without increasing low-density lipoprotein-cholesterol levels: A phase 4, randomized study	Atherosclerosis	292	163-170	2020
Daisaku Masuda, <u>Shizuya Yamashita</u>	Postprandial glucose and triglyceride increases along with the endothelial malfunction were attenuated by the administration of SGLT2 inhibitor, empagliflozin	J Atherosclerosis Thromb		doi: 10.5551/jat.ED124. [Epub ahead of print]	2020
Takeshi Okada, Mizuki Sumida, Tohru Ohama, Yuuki Katayama, Hiroyasu Inui, Koutaro Kanno, Daisaku Masuda, <u>Masahiro Koseki</u> , Makoto Nishida, Norihiro Kayahara, Yasushi Sakata, <u>Shizuya Yamashita</u>	Development of an enzyme-linked immunosorbent assay for oxidized high density lipoprotein and its clinical application for cardiovascular risk assessment	J Atherosclerosis Thromb			
<u>Shizuya Yamashita</u>	New life for old heart drug	TRI (Translational Research Center for Medical Innovation) Advances: Research Highlight			2020
<u>Shizuya Yamashita</u> , Yuji Matsuzawa	Adiposity measures and mortality in an Asian population	Nature Reviews Endocrinology			

Cesare R Sirtori, <u>Shizuya Yamashita</u> , Maria Francesca Greco, Alberto Corsini, Gerald Watts, Massimiliano Ruscica	Recent advances in synthetic pharmacotherapies for dyslipidemia	Eur J Prevent Cardiol	27(15)	1576-1596	2020
Kimura M, Horie T, Baba O, Ide Y, Tsuji S, Ruiz Rodriguez R, Watanabe T, Yamasaki T, Otani C, Xu S, Miyasaka Y, Nakashima Y, Kimura T, <u>Ono K</u>	Homeobox A4 suppresses vascular remodeling by repressing YAP/TEAD transcriptional activity	EMBO Rep	21(4)	e48389. doi: 10.15252/embr.201948389.	2020
Yamamoto H, Kihara Y, Fujimoto S, <u>Daida H</u> , Kobuke K, Iwanaga Y, Miyazaki S, Kawasaki T, Fujii T, Kuribayashi S	Predictive value of the coronary artery calcium score and advanced plaque characteristics: Post hoc analysis of the PREDICT registry	J Cardiovasc Comput Tomogr		9:S1934-5925(20)30371-3. doi: 10.1016/j.jcct.2020.06.198. Online ahead of print. PMID: 32826204	2020
Nishitani-Yokoyama M, Miyauchi K, Shimada K, Yokoyama T, Ouchi S, Aikawa T, Kunimoto M, Yamada M, Honzawa A, <u>Okazaki S</u> , Tsujita H, Kobas, <u>Daida H</u>	Preliminary Pilot Study of Combined Effects of Physical Activity and Achievement of LDL-Cholesterol Target on Coronary Plaque Volume Changes in Patients with Acute Coronary Syndrome	J Clin Med	9(5)	1578 doi: 10.3390/jcm9051578. PMID: 32455937	2020
Kodama S, Fujihara K, Horikawa C, Sato T, Iwanaga M, Yamada T, Kato K, Watanabe K, <u>Shimano H</u> , Izumi T, Sonoe H	Diabetes mellitus and risk of new-onset and recurrent heart failure: a systematic review and meta-analysis	ESC HeartFail	7(5)	2146-2174 doi: 10.1093/ehf2.12782. Epub 2020 Jul 29. PMID:32725969; PMCID: PMC7524078.	2020

Manda CM, Hokimoto T, Okura T, Isoda H, <u>Shimano H</u> , Wagatsuma Y	Handgrip strength predicts new prediabetes cases among adults: A prospective cohort study	Prev Med Rep	17	101056 doi: 10.1016/j.pmedr.2020.101056. PMID: 32071846; PMCID: PMC7016270.	2020
Tada H, Takamura M, <u>Kawashirima</u>	Familial Hypercholesterolemia: A Narrative Review on Diagnosis and Management Strategies for Children and Adolescents	Vasc Health Risk Manag	17	59-67	2021
Kido, J., Matsumoto, S., Ito, T., Hirose, S., Fukui, K., Kojima-Ishii, K., Mushimoto, Y., Yoshida, S., Ishige, M., Sakai, N., <u>Nakamura, K.</u>	Physical, cognitive, and social status of patients with urea cycle disorders in Japan	Molecular Genetics and Metabolism Reports	27	100724	2021
Okuyama, T., Etou, Y., Sakai, N., <u>Nakamura, K.</u> , Yamamoto, T., Yamaoka, M., Ikeda, T., So, S., Tanizawa, K., Sonoda, H., Sato, Y.	A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II	Molecular Therapy	29 (2)	671-679	2021
Katayama, D., Baba, H., Kuwabara, T., Kido, J., Mitsubuchi, H., Matsumoto, S., <u>Nakamura, K.</u>	SGLT2 inhibition alleviated hyperglycemia, glucose intolerance, and dumping syndrome-like symptoms in a patient with glycogen storage disease type Ia: a case report	Journal of Medical Case Reports	15		2021

Omote K, Yokota I, Nagai T, Sakuma I, Nakagawa Y, Kamiya K, Iwata H, Miyachi K, Ozaki Y, Hibi K, Hiro T, Fukumoto Y, Mori H, Hokimoto S, Ohashi Y, Ohtsu H, Ogawa H, <u>Daida H</u> , Imuro S, Shimokawa H, Saito Y, Kimura T, Matsuzaki M, Nagai R, Anzai T	High-Density Lipoprotein Cholesterol and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Statins: An Observation from the REAL-CAD Study	J Atherosclerosis Thromb			2021
Minami-Takano A, Iwata H, Miyosawa K, Shiozawa T, Hayashi H, Funamizu T, Ishii K, Nozaki Y, Tabuchi H, Sekita G, Shimada K, Sumiyoshi M, Nakazato Y, <u>Daida H</u> , Minamino T	The association between impairment of HDL cholesterol efflux capacity and atrial remodeling in atrial fibrillation	Sci Rep	11	3547	2021
Goto M, Hagiwara A, Fujita S, Hori M, Kamagata K, Aoki S, Abe O, Sakamoto H, Sakano Y, Kyogoku S, <u>Daida H</u>	Influence of Mild White Matter Lesions on Voxel-based Morphometry	Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine	20	40-6	2021

Fukase T, Dohi T, Kato Y, Chikata Y, Takahashi N, Endo H, Doi S, Nishiyama H, Okai I, Iwata H, Okazaki S, Isoda K, Miyachi K, <u>Daida H</u> , Minamino T	Long-term clinical outcomes and cause of death after endovascular treatment for femoropopliteal artery lesions	J Cardiol	77	417-23	2021
Aoshima C, Fujimoto S, Kawaguchi YO, Dohi T, Kamo Y, Takamura K, Hiki M, Kato Y, Okai I, Okazaki S, Kumamaru KK, Aoki S, <u>Daida H</u>	Plaque characteristics on coronary CT angiography associated with the positive findings of fractional flow reserve and instantaneous wave-free ratio	Heart Vessels	36	461-71	2021
Doi T, Hori M, <u>Harada-Shiba M</u> , Kataoka Y, Onozuka D, Nishimura K, Nishikawa R, Tsuda K, <u>Ogura M</u> , Son C, Miyamoto Y, Noguchi T, Shimokawa H, Yasuda S.	Patients with <i>LDLR</i> and <i>PCSK9</i> Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia	J Am Heart Assoc	A10	E018263	2021
Nishikawa R, Furuhashi M, Hori M, <u>Ogura M</u> , <u>Harada-Shiba M</u> , Okada T, Koseki M, Kujiraoka T, Hattori H, Ito R, Muranaka A, Kokubu N, Miura T.	A Resuscitated Case of Acute Myocardial Infarction with both Familial Hypercholesterolemia Phenotype Caused by Possibly Oligogenic Variants of the <i>PCSK9</i> and <i>ABCG5</i> Genes and Type I <i>CD36</i> Deficiency	J Atheroscler Thromb	In press	In press	2021

Michikura M, Ogura M, Hori M, Furuta K, Hosoda K, Harada-Shiba M.	Achilles Tendon Softness as a New Tool for Diagnosing Familial Hypercholesterolemia	JACC Cardiovasc Imaging	In press	In press	2021
Jiuyang Chang, Masahiro, Koseki, Ayami Saga, Kotaro Kanno, Tomoaki Higo, Daisuke Okuzaki, Takeshi Okada, Hiroyasu Inui, Masumi Asaji, Yinghong Zhu, Yoshihiro Kamada, Masafumi Ono, Toshiji Saibara, Ikuyo Ichi, Tohru Ohama, Makoto Nishida, Shizuya Yamashita, Yasushi Sakata	Dietary oxysterol, 7-ketocholesterol, accelerates hepatic lipid accumulation and macrophage infiltration in obese mice	Front Endocrinol (Lausanne)		Mar 10;11:614692. doi: 10.3389/fendo.2020.614692. eCollection	2020
Shizuya Yamashita, Daisaku Masuda, Yuji Matsuzawa	New horizons for an old, mysterious drug probucol	J Atheroscler Thromb	28(2)	100-102	2021

<p>Hidenori Arai, Hideaki Bujo, Daisaku Masuda, Toshiyuki Ishibashi, Satoshi Nakagawa, Koichi Yamashiro, Kenichiro Tanabe, Kenichi Kagimura, Hyun-Jae Kang, Moo Hyun Kim, Jidong Sung, Sang-Hyun Kim, Cheol-Ho Kim, Jeong Euy Park, Junbo Ge, Byung-Hee Oh, Toru Kita, Masunori Matsuzaki, Yasushi Saito, Masanori Fukushima, Yuji Matsuzawa, Shizuya Yamashita</p>	<p>Integrated analysis of two probucol trials for the secondary prevention of atherosclerotic cardiovascular events -PROSPECTIVE and IMPACT-</p>	<p>J Atherosclerosis Thromb</p>	<p>in press</p>	<p>in press</p>	
<p>Shizuya Yamashita, Daisaku Masuda, Mariko Harada-Shiba, Hidenori Arai, Hideaki Bujo, Shun Ishibashi, Hiroyuki Daida, Nobuhiko Koga, Shinichi Oikawa on Behalf of the FAME Study Group</p>	<p>Effectiveness and safety of lipid-lowering drug treatments in Japanese patients with familial hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study</p>	<p>J Atherosclerosis Thromb</p>	<p>in press</p>	<p>in press</p>	
<p>Koutaro Yokote, Shizuya Yamashita, Hidenori Arai, Eiichi Araki, Mitsunori Matsushita, Toshiaki Nojima, Hiideki Suganami, Shun Ishibashi</p>	<p>Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: A pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials</p>	<p>Cardiovascular Diabeto</p>	<p>in press</p>	<p>in press</p>	

Daisaku Masuda, Shizuya Yamashita	Editorial: Serum HDL-cholesterol level does not influence cardiovascular event rate under sufficient lowering of LDL-cholesterol by pitavatin in patients with stable coronary artery disease	J Atherosclerosis Thromb		doi: 10.5551/jat.ED165. Online ahead of print	2021
Masatsune Ogura, Mariko Harada-Shiba, Daisaku Masuda, Hidenori Arai, Hideaki Bujo, Shun Ishibashi, Hiroyuki Daida, Nobuhiko Koga, Shinichi Oikawa, Shizuya Yamashita, on Behalf of the FAME Study Group	Factors Associated with Carotid Atherosclerosis and Achilles Tendon Thickness in Japanese Patients with Familial Hypercholesterolemia: A Subanalysis of the Familial Hypercholesterolemia Expert Forum (FAME) Study	J Atherosclerosis Thromb	in press	in press	
Nishikawa R, Furuhashi M, Hori M, Ogura M, Harada-Shiba M, Okada T, Koseki M, Kujiraoka T, Hattori H, Ito R, Muranaka A, Kokubu N and Miura T.	A Resuscitated Case of Acute Myocardial Infarction with both Familial Hypercholesterolemia Phenotype Caused by Possibly Oligogenic Variants of the PCSK9 and ABCG5 Genes and Type I CD36 Deficiency	J Atherosclerosis Thromb			2021
Nakamura M, Aoki J, Arai H, Hirayama A, Nohara A, Murakami Y, Ozaki A and Harada-Shiba M	Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome: EXPLORE-J	J Atherosclerosis Thromb			2021



<p>Michikura M, <u>Ogura M</u>, <u>Hori M</u>, <u>Furuta K</u>, <u>Hosoda K</u> and <u>Harada-Shiba M</u></p>	<p>Achilles Tendon Softness as a New Tool for Diagnosing Familial Hypercholesterolemia</p>	<p>JACC Cardiovascular Imaging</p>			<p>2021</p>
<p><u>Harada-Shiba M</u></p>	<p>How Can We Improve the Diagnosis Rate of Familial Hypercholesterolemia by Amending Diagnosis Criteria?</p>	<p>Circ J</p>			<p>2021</p>
<p>Doi T, <u>Hori M</u>, <u>Harada-Shiba M</u>, <u>Kataoka Y</u>, <u>Onozuka D</u>, <u>Nishimura K</u>, <u>Nishikawa R</u>, <u>Tsuda K</u>, <u>Ogura M</u>, <u>Son C</u>, <u>Miyamoto Y</u>, <u>Noguchi T</u>, <u>Shimokawa H</u> and <u>Yasuda S</u></p>	<p>Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia</p>	<p>J Am Heart Assoc</p>		<p>10:e018263</p>	<p>2021</p>

<p>Nohara A, Tada H, Ogura M, Okazaki S, Ono K, Shimano H, Daida H, Dobashi K, Hayashi T, Horii M, Matsuki K, Minamino T, Yokoyama S, Harada-Shiba M; Committee on Primary Dyslipidemia under the Research Program on Rare and Intractable Disease of the Ministry of Health, Labour and Welfare of Japan.</p>	<p>Homozygous Familial Hypercholesterolemia.</p>	<p>J Atheroscler Thromb</p>	<p>In press</p>	<p>In press</p>	<p>2021</p>
<p>Kuroda M, Bujo H, Yokote K, Murano T, Yamaguchi T, Ogura M, Ikewaki K, Koseki M, Takeuchi Y, Nakatsuka A, Hori M, Matsuki K, Miida T, Yokoyama S, Wada J, Harada-Shiba M; Committee on Primary Dyslipidemia under the Research Program on Rare and Intractable Disease of the Ministry of Health, Labour and Welfare of Japan.</p>	<p>Current Status of Familial LCAT Deficiency in Japan.</p>	<p>J Atheroscler Thromb</p>	<p>In press</p>	<p>In press</p>	<p>2021</p>

<p>Tada H, Nomura A, Ogura M, Ike waki K, Ishigaki Y, Inagaki K, Tsukamoto K, Dobashi K, Nakamura K, Hori M, Matsuki K, Yamashita S, Yokoyama S, Kawashiri MA, Harada-Shiba M; Committee on Primary Dyslipidemia under the Research Program on Rare and Intractable Disease of the Ministry of Health, Labour and Welfare of Japan.</p>	<p>Diagnosis and Management of Sitosterolemia 2021.</p>	<p>J Atheroscler Thromb</p>	<p>In press</p>	<p>In press</p>	<p>2021</p>
<p>Masahiro Koseki, Shizuya Yamashita, Masatsune Ogura, Yasushi Ishigaki, Koh Ono, Kazuhisa Tsukamoto, Mika Hori, Kota Matsuki, Shinji Yokoyama, Mariko Harada-Shiba, on behalf of the Committee on Primary Dyslipidemia under the Research Program on Rare and Intractable Disease of the Ministry of Health, Labour and Welfare of Japan</p>	<p><b>Current Diagnosis and Management of Truncal Artery Disease</b></p>	<p>J Atheroscler Thromb</p>	<p>In press</p>	<p>In press</p>	<p>2021</p>

<p>Okazaki H, Goto da T, Ogura M, Ishibashi S, Inagaki K, Daida H, Hayashi T, Hori M, Masuda D, Matsuki K, Yokoyama S, Harada-Shiba M; Committee on Primary Dyslipidemia under the Research Program on Rare and Intractable Disease of the Ministry of Health, Labour and Welfare of Japan.</p>	<p>Current Diagnosis and Management of Primary Chylomicronemia.</p>	<p>J Atherosclerosis Thromb</p>	<p>In press</p>	<p>In press</p>	<p>2021</p>
<p>Koyama S, Sekijima Y, Ogura M, Hori M, Matsuki K, Miida T, Harada-Shiba M; Committee on Primary Dyslipidemia under the Research Program on Rare and Intractable Disease of the Ministry of Health, Labour and Welfare of Japan.</p>	<p>Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments</p>	<p>J Atherosclerosis Thromb</p>	<p>In press</p>	<p>In press</p>	<p>2021</p>

<p>Manabu Takahashi, Hiroaki Okazaki, Ken Ohashi, Masatsune Ogura, Shun Ishibashi, Sachiko Okazaki, Satoshi Hirayama, Mika Hori, Kota Matsuki, Shinji Yokoyama, Mariko Harada-Shiba, on behalf of the Committee on Primary Dyslipidemia under the Research Program on Rare and Intractable Disease of the Ministry of Health, Labour and Welfare of Japan</p>	<p>Current Diagnosis and Management of Abetalipoproteinemia</p>	<p>J Atheroscler Thromb</p>	<p>In press</p>	<p>In press</p>	<p>2021</p>
---	---	-----------------------------	-----------------	-----------------	-------------